Everyday Health (EVDY) 10-K 11 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 04, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Everyday Health, Inc.
Entity Central Index Key	1,358,483
Trading Symbol	evdy
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		32,866,363
Entity Public Float			$ 296.1
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 30,097	$ 50,729
Accounts receivable, net of allowance for doubtful accounts of $909 and $637 as of December 31, 2015 and 2014, respectively	90,356	68,007
Prepaid expenses and other current assets	4,662	5,529
Total current assets	125,115	124,265
Property and equipment, net	28,565	25,502
Goodwill	165,271	127,115
Intangible assets, net	43,746	30,716
Other assets	6,901	5,237
Total assets	369,598	312,835
Current liabilities:
Accounts payable and accrued expenses	38,563	31,722
Deferred revenue	8,655	6,740
Current portion of long-term debt	6,775	3,000
Other current liabilities	11,890	965
Total current liabilities	65,883	42,427
Long-term debt	104,281	87,000
Deferred tax liabilities	7,570	6,017
Other long-term liabilities	$ 11,595	$ 4,105
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.01 par value: 10,000,000 shares authorized at December 31, 2015 and 2014; no shares issued and outstanding at December 31, 2015 and 2014
Common stock, $0.01 par value: 90,000,000 shares authorized at December 31, 2015 and 2014; 32,707,606 and 31,489,196 shares issued and outstanding at December 31, 2015 and 2014, respectively	$ 327	$ 314
Treasury stock	(55)	(55)
Additional paid-in capital	310,727	292,117
Accumulated deficit	(130,730)	(119,090)
Total stockholders' equity	180,269	173,286
Total liabilities and stockholders' equity	$ 369,598	$ 312,835

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts (in Dollars)	$ 909	$ 637
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	32,707,606	31,489,196
Common stock, shares outstanding	32,707,606	31,489,196

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues
Advertising and sponsorship revenues	$ 209,093	$ 166,465	$ 134,893
Premium services revenues	22,898	17,860	20,957
Total revenues	231,991	184,325	155,850
Operating expenses:
Cost of revenues	66,923	49,296	43,338
Sales and marketing	74,761	48,605	44,385
Product development	55,920	44,541	43,759
General and administrative	39,487	30,041	27,462
Total operating expenses	237,091	172,483	158,944
Income (loss) from operations	(5,100)	11,842	(3,094)
Interest expense, net	(5,236)	(3,711)	(8,442)
Other expense		(4,114)	(359)
Income (loss) from continuing operations before (provision) benefit for income taxes	(10,336)	4,017	(11,895)
(Provision) benefit for income taxes	(1,304)	8,666	(1,102)
Income (loss) from continuing operations	(11,640)	12,683	(12,997)
Loss from discontinued operations, net of tax			(5,239)
Net income (loss)	(11,640)	12,683	(18,236)
Series G preferred stock deemed dividend		(8,079)
Net income (loss) attributable to common stockholders	$ (11,640)	$ 4,604	$ (18,236)
Basic net income (loss) attributable to common stockholders per common share:
Net income (loss) attributable to common stockholders from continuing operations	$ (0.36)	$ 0.19	$ (2.55)
Net loss attributable to common stockholders from discontinued operations, net of tax			(1.03)
Net income (loss) attributable to common stockholders	(0.36)	0.19	(3.57)
Diluted net income (loss) attributable to common stockholders per common share:
Net income (loss) attributable to common stockholders from continuing operations	(0.36)	0.17	(2.55)
Net loss attributable to common stockholders from discontinued operations, net of tax			(1.03)
Net income (loss) attributable to common stockholders	$ (0.36)	$ 0.17	$ (3.57)
Weighted-average common shares outstanding:
Basic (in shares)	31,977,246	24,259,395	5,103,351
Diluted (in shares)	31,977,246	26,911,782	5,103,351

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Redeemable convertible preferred stock	Common Stock	Common StockIPO	Treasury stock	Additional paid in capital	Additional paid in capitalIPO	Accumulated deficit	Total	IPO
Balance at Dec. 31, 2012	$ 158,766	$ 49			$ 26,759		$ (105,458)	$ (78,650)
Balance (in Shares) at Dec. 31, 2012	26,820,270	4,860,855
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 2			787			789
Exercise of stock options (in Shares)		183,501
Warrant issued in connection with credit facility					149			149
Issuance of common stock		$ 3			2,992			2,995
Issuance of common stock (in Shares)		330,022
Purchase of treasury stock				$ (55)				(55)
Purchase of treasury stock (in Shares)		(7,900)
Stock-based compensation expense related to employee stock options					3,039			3,039
Net income (loss)							(18,236)	(18,236)
Balance at Dec. 31, 2013	$ 158,766	$ 54		(55)	33,726		(123,694)	(89,969)
Balance (in Shares) at Dec. 31, 2013	26,820,270	5,366,478
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 11			7,291			7,302
Exercise of stock options (in Shares)		1,139,891
Exercise of warrants		$ 6			$ (6)
Exercise of warrants (in shares)		645,284
Issuance of common stock in connection with employee stock purchase plan		$ 1			$ 1,591			1,592
Issuance of common stock in connection with employee stock purchase plan (in Shares)		138,184
Issuance of common stock for acquired business		$ 1			918			919
Issuance of common stock in connection with acquisitions (in shares)		65,710
Issuance of common stock			$ 57			$ 70,565			$ 70,622
Issuance of common stock (in Shares)			5,676,414
Conversion of preferred stock	$ (158,766)		$ 184		158,582			158,766
Conversion of preferred stock (in Shares)	(26,820,270)		18,457,235
Series G preferred stock deemed dividend					8,079		(8,079)
Reclassification of liability warrants to equity warrants						$ 1,140
Stock-based compensation expense					9,100			9,100
Warrant issued in connection with website partner agreement					1,131			1,131
Net income (loss)							12,683	12,683
Balance at Dec. 31, 2014		$ 314		(55)	292,117		(119,090)	173,286
Balance (in Shares) at Dec. 31, 2014		31,489,196
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 4			2,585			2,589
Exercise of stock options (in Shares)		358,077
Common stock issued for settlement of restricted stock units, net of 100,690 shares withheld to satisfy income tax withholding obligations		$ 2			(625)			(623)
Common stock issued for settlement of restricted stock units, net of 100,690 shares withheld to satisfy income tax withholding obligations (in shares)		179,296
Exercise of warrants		$ 1			(1)
Exercise of warrants (in shares)		99,881
Issuance of common stock in connection with employee stock purchase plan		$ 3			2,008			2,011
Issuance of common stock in connection with employee stock purchase plan (in Shares)		271,623
Issuance of common stock for acquired business		$ 3			3,707			3,710
Issuance of common stock in connection with acquisitions (in shares)		309,533
Stock-based compensation expense					10,936			10,936
Net income (loss)							(11,640)	(11,640)
Balance at Dec. 31, 2015		$ 327		$ (55)	$ 310,727		$ (130,730)	$ 180,269
Balance (in Shares) at Dec. 31, 2015		32,707,606

Consolidated Statements of Red6

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Issuance of common stock in connection with IPO		$ 8,848
Shares withheld to satisfy income tax withholding obligations	100,690

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net income (loss)	$ (11,640)	$ 12,683	$ (18,236)
Less loss from discontinued operations, net of tax			(5,239)
Income (loss) from continuing operations	(11,640)	12,683	(12,997)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	20,408	14,943	15,450
Amortization of video and television costs			632
Provision for doubtful accounts	326	315	62
Stock-based compensation	10,936	9,100	2,969
Amortization and write-off of deferred financing costs	540	4,389	1,646
Asset impairment charge	1,416		1,261
Provision (benefit) for deferred income taxes	952	(9,071)	962
Changes in operating assets and liabilities:
Accounts receivable	(17,490)	(12,437)	(10,683)
Prepaid expenses and other current assets	982	1,489	(2,725)
Additions to video and television costs			(453)
Accounts payable and accrued expenses	5,420	(1,942)	7,529
Deferred revenue	1,183	(68)	1,744
Other current liabilities	154	58	(426)
Other long-term liabilities	7,759	581	951
Net cash provided by operating activities from continuing operations	20,946	20,040	5,922
Net cash used in operating activities from discontinued operations			(4,250)
Net cash provided by operating activities	20,946	20,040	1,672
Cash flows from investing activities
Additions to property and equipment, net	(14,481)	(14,754)	(10,654)
Proceeds from sale of business		400	600
Payment for businesses purchased, net of cash acquired	(47,316)	(65,000)	(6,736)
Payment of security deposits and other assets	(1,413)	131	(717)
Net cash used in investing activities	(63,210)	(79,223)	(17,507)
Cash flows from financing activities
Net proceeds from common stock issuance		70,622
Proceeds from the exercise of stock options	2,633	7,939	101
Principal payments on capital lease obligations	(642)	(659)	(456)
Payments of credit facility financing costs	(792)	(2,899)	(68)
Payment for purchase of treasury stock			(55)
Tax withholdings related to net share settlements of RSUs	(623)
Net cash provided by financing activities	21,632	93,670	8,189
Net increase (decrease) in cash and cash equivalents	(20,632)	34,487	(7,646)
Cash and cash equivalents, beginning of year	50,729	16,242	23,888
Cash and cash equivalents, end of year	30,097	50,729	16,242
Former Revolving Credit Facility
Cash flows from financing activities
Repayments of principal		(30,000)	(850)
Borrowings			7,350
Former Term Loan
Cash flows from financing activities
Repayments of principal		(41,333)	(2,833)
Borrowings			$ 5,000
Revolving Credit Facility
Cash flows from financing activities
Repayments of principal	(10,000)	(32,300)
Borrowings	25,000	62,300
Term Loan Facility
Cash flows from financing activities
Repayments of principal	(2,444)	(1,000)
Borrowings	$ 8,500	$ 61,000

Business

Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Everyday Health, Inc. (the “Company”) operates a leading marketing and communications platform for healthcare marketers seeking to engage and influence consumers and healthcare professionals. The Company was incorporated in the State of Delaware in January 2002 as Agora Media Inc., and changed its name to Waterfront Media Inc. in January 2004. In January 2010, the Company changed its name to Everyday Health, Inc. to better align its corporate identity with the Everyday Health

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of the acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, current business factors and other available information. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition and deferred revenue, allowance for doubtful accounts, internal software development costs and website development costs, valuation of long-lived assets, goodwill and other intangible assets, income taxes and stock-based compensation. Reclassifications Certain reclassifications have been made to the prior year financial statements to conform to the December 31, 2015 presentation. Initial Public Offering On April 2, 2014, the Company closed its initial public offering of common stock (“IPO”). The IPO, including the additional shares issued and sold on April 30, 2014 pursuant to the underwriters’ exercise of their over-allotment option, resulted in net proceeds of $70,622, after deducting underwriting discounts and commissions and offering costs borne by the Company totaling $8,848. As a result of the IPO, the Company issued and sold 5,676,414 shares of common stock at a public offering price of $14.00 per share, and all of the Company’s redeemable convertible preferred stock outstanding automatically converted into an aggregate of 18,457,235 shares of common stock, including 577,055 additional shares of common stock related to the Series G redeemable convertible preferred stock ratchet provision (refer to Note 10 for further discussion). In addition, certain selling stockholders exercised stock options and warrants for an aggregate of 339,053 shares of common stock, 149,839 shares of common stock were issued upon the automatic net exercise of a warrant, and outstanding warrants to purchase 222,977 shares of redeemable convertible preferred stock automatically converted into warrants to purchase an aggregate of 148,650 shares of common stock, which resulted in the reclassification of the preferred stock warrant liability of $1,140 to additional paid-in capital. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the lease term or the estimated useful life of the improvement. Operating Leases The Company recognizes rent expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term including reasonably assured renewal periods, net of lease incentives, from the time that the Company controls the leased property. Tenant improvement allowances are recognized as a reduction to rent expense on a straight-line basis over the lease term. Internal Software Development Costs The Company incurs costs to develop software for internal use. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of payroll and related benefits, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. Website Development Costs The Company incurs costs to develop its websites, tools and applications. The Company expenses all costs that relate to the planning and post-implementation phases of website development as product development expense. Costs incurred in the development phase, consisting principally of third-party consultants and related charges, and the costs of content determined to provide a future economic benefit, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years. Goodwill Goodwill represents the excess cost over fair value of the identifiable net assets of acquired businesses. Goodwill is tested for impairment on an annual basis as of October 1, and whenever events or circumstances indicate that the carrying value of the asset may not be recoverable. An initial qualitative analysis is performed evaluating whether any events and circumstances occurred or exist that provide evidence that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on this analysis, indicators deem it more likely than not that the fair value of the reporting unit is less than its carrying amount, then the two-step quantitative impairment test is performed; otherwise, no further step is required. If and when needed to complete the two-step quantitative assessment, the fair value of goodwill is estimated using a combination of an income approach based on the present value of estimated future cash flows, and a market approach examining transactions in the marketplace involving the sale of stocks of similar publicly traded companies, or the sale of entire companies engaged in operations similar to those of the Company. As the Company has one operating segment and one reporting unit, the first step of the impairment test requires a comparison of the fair value of the reporting unit, or business enterprise value as a whole, to the carrying value of the Company’s invested capital. If the carrying amount exceeds the fair value, there is indication that an impairment may exist, and a second step must be performed. If the carrying amount is less than the fair value, no indication of impairment exists, and a second step is not performed. The evaluation of the Company’s goodwill indicated that the carrying value of the asset was less than the fair value and, accordingly, there was no impairment loss recognized for the years ended December 31, 2015, 2014 and 2013. Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with definite lives, for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The intangible assets with definite lives consist principally of trade names and customer relationships. Definite-lived intangible assets are amortized over their estimated useful lives, ranging from three to ten years, using the straight-line method which approximates the pattern in which economic benefits are consumed. In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets and other long-lived assets on an ongoing basis. During the year ended December 31, 2015, an impairment charge of $1,416 was recorded related to certain software development projects which the Company decided not to move forward with. The $1,416 charge is included in product development expense in the accompanying consolidated statements of operations. There were no indicators of impairment of the Company’s long-lived assets during the year ended December 31, 2014. During the year ended December 31, 2013, the Company recorded an impairment charge of $1,190 related to the consolidation and reorganization of certain website content and tools. This $1,190 charge is included in product development expense in the accompanying consolidated statements of operations. Revenue Recognition and Deferred Revenue The Company generates its revenue from (i) advertising and sponsorships and (ii) premium services, including consumer subscriptions, SaaS-based licensing fees and other licensing fees. Advertising revenue is recognized in the period in which the advertisement is delivered. Revenue from sponsorships, which includes time and materials based creative services, is recognized over the period the Company substantially satisfies its contractual obligations as required under the respective sponsorship agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on management’s best estimate of selling price. Subscriptions are generally paid in advance on a monthly, quarterly or annual basis. Subscription revenue, after deducting refunds and charge-backs, is recognized on a straight-line basis ratably over the subscription periods. SaaS and other licensing revenue is generally recognized on a straight-line basis ratably over the life of the contract. Deferred revenue relates to: (i) subscription fees for which amounts have been collected but for which revenue has not been recognized, and (ii) advertising and sponsorship fees and licensing fees billed in advance of when the revenue is to be earned. Cost of Revenues Cost of revenues consists principally of the expenses associated with aggregating the total audience across the Company’s websites, including (i) royalty expenses for licensing content for certain websites and for the portion of advertising revenue the Company pays to the owners of certain other websites, and (ii) media costs associated with audience aggregation activities. Cost of revenues also includes market research incentives, direct mail marketing and fulfillment costs, as well as out-of-pocket costs related to creative services and costs associated with subscription fees for our premium services, ad serving and other expenses. Royalty expense amounted to $23,805, $20,937 and $18,673 for the years ended December 31, 2015, 2014 and 2013, respectively. Media costs consist primarily of fees paid to online publishers, Internet search companies and other media channels for search engine and database marketing, and display and television advertising. These media activities are attributable to revenue-generating and audience aggregation events, designed to increase the audience to the websites the Company operates, increase the number of subscribers to premium services and grow the Company’s registered user base. Media costs totaled $32,198, $24,973 and $22,437 for the years ended December 31, 2015, 2014 and 2013, respectively. Other Expense There were no charges reflected as other expense for the years ended December 31, 2015 and 2013. In connection with the refinancing of its credit facilities in 2014, the Company wrote-off unamortized deferred financing costs totaling $2,845 and incurred prepayment fees of $1,016, which, together with the mark-to-market adjustment on certain preferred stock warrants of $253, is reflected as other expense in the accompanying consolidated statements of operations for the year ended December 31, 2014. Income Taxes The Company accounts for taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the tax and financial statement reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset. As a result of the Company’s historical operating performance and the cumulative net losses incurred to date, the Company does not have sufficient objective evidence to support the recovery of the net deferred tax assets. Accordingly, the Company has established a valuation allowance against net deferred tax assets for financial reporting purposes to the extent it is determined that such deferred tax assets are not more likely than not to be realized. The Company accounts for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more likely than not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense. Comprehensive Income (Loss) Other than the Series G preferred stock deemed dividend reflected in the accompanying statement of operations for the year end December 31, 2014 (see Note 10), the Company has no items of other comprehensive income (loss). Fair Value of Financial Instruments Due to their short-term maturities, the carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other highly liquid money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of the Company’s debt approximates the recorded amounts as the interest rates on the credit facilities are based on market interest rates. Stock-Based Compensation The Company accounts for all share-based payments, including grants of employee stock options and restricted stock units, based on the fair value of the award measured at the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of the stock option awards and stock purchase rights provided under the 2014 Employee Stock Purchase Plan, or ESPP. The fair value of restricted stock unit awards represents the closing price of the Company’s common stock on the date of grant. Stock-based compensation expense is recognized over the period during which the recipient provides services, generally the vesting period, net of estimated forfeitures. Business Concentrations, Accounts Receivable and Credit Risk Financial instruments which potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. Cash and cash equivalents includes U.S. Treasury securities and other money market funds. Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the Company’s customer base and the ongoing credit evaluation of its customers. For the years ended December 31, 2015 and 2014, no advertising customer accounted for greater than 10% of total revenues. For the year ended December 31, 2013, one advertising customer accounted for 12% of total revenues. As of December 31, 2015 and 2014, no advertising customers accounted for greater than 10% of total accounts receivable. As many of the Company’s advertising customers work through the same advertising agencies, the Company also monitors the concentration of accounts receivable at the agency level. As of December 31, 2015 and 2014, no advertising agency accounted for greater than 10% of accounts receivable. The Company’s net accounts receivable balance of $90,356 and $68,007 reflected in the accompanying balance sheets as of December 31, 2015 and 2014, respectively, include unbilled accounts receivable of $12,224 and $7,064 as of December 31, 2015 and 2014, respectively, which primarily represent revenue earned and accrued in the respective fiscal years, billed subsequent to year end. An allowance for doubtful accounts is established with respect to accounts receivable that the Company has determined to be doubtful of collection, based upon factors surrounding the credit risk of customers, historical experience and other information. The following table summarizes the activity of the allowance for doubtful accounts: Year Ended December 31, 2015 2014 2013 Balance at beginning of year $ 637 $ 530 $ 651 Bad debt provision 326 384 251 Write-offs (54 ) (277 ) (372 ) Balance at end of year $ 909 $ 637 $ 530 Business Combinations The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. During the measurement period, which is up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, based on additional information impacting the assigned estimated fair values. Segment Information The Company and its subsidiaries are organized in a single operating segment, providing digital health marketing and communications solutions, and the Company also has one reportable segment. Substantially all of the Company’s revenues are derived from U.S. sources. Net Income (Loss) Attributable to Common Stockholders per Common Share Basic net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, adjusted to reflect potentially dilutive securities. Potentially dilutive securities consist of incremental shares issuable upon the assumed exercise of stock options, restricted stock units and warrants using the treasury stock method, convertible preferred shares using the “if converted” method, and employee withholdings to purchase common stock under the Company’s ESPP. Due to the net losses for the years ended December 31, 2015 and 2013, the aforementioned potentially dilutive securities were not included in the computation of diluted net loss per common share because the effect would have been anti-dilutive. The basic and diluted net income (loss) attributable to common stockholders per common share is calculated as follows for the periods presented: Year Ended December 31, 2015 2014 2013 Numerator: Income (loss) from continuing operations $ (11,640 ) $ 12,683 $ (12,997 ) Loss from discontinued operations, net of tax — — (5,239 ) Net income (loss) (11,640 ) 12,683 (18,236 ) Series G preferred stock deemed dividend — (8,079 ) — Net income (loss) attributable to common stockholders $ (11,640 ) $ 4,604 $ (18,236 ) Denominator: Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share 31,977,246 24,259,395 5,103,351 Dilutive securities: Stock option awards — 2,235,059 — Warrants to purchase common stock — 412,305 — Employee stock purchase plan — 5,023 — Total weighted-average diluted shares 31,977,246 26,911,782 5,103,351 Basic net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.19 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.19 $ (3.57 ) Diluted net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.17 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.17 $ (3.57 ) The following securities were outstanding for the periods presented below and have been excluded from the calculation of diluted net income (loss) attributable to common stockholders per common share because the effect is anti-dilutive: Year Ended December 31, 2015 2014 2013 Warrants to purchase common stock 76,659 — 583,247 Warrants to purchase redeemable convertible preferred stock — — 148,650 Redeemable convertible preferred stock — — 17,880,180 Stock option awards 6,252,223 1,337,766 5,366,785 Unvested RSU awards 453,349 — — Employee stock purchase plan 100,722 — — Total weighted-average anti-dilutive securities 6,882,953 1,337,766 23,978,862 Foreign Currency The financial statements and transactions of the Company’s foreign subsidiary are maintained in its local currency. The translation of foreign currencies into United States dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date, and for revenue and expense accounts using average exchange rates during the year. Foreign currency gains or losses are included in the consolidated statements of operations and were not material in any of the periods presented. Recently Issued and Adopted Accounting Standards In April 2014, the Financial Accounting Standards Board (“FASB”) issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In May 2014, the FASB issued guidance which provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The guidance was originally to be effective for annual and interim periods beginning after December 15, 2016. In August 2015, the FASB approved a one year deferral of the effective date to December 15, 2017 and early adoption is permitted, but not before the original effective date of December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method and is currently evaluating the effect that the new standard will have on the consolidated financial statements and related disclosures. In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In April 2015, the FASB issued updated guidance on the presentation of debt issuance costs in financial statements. The new guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This guidance will be effective for the Company beginning in the first quarter of 2016 on a retrospective basis for all periods presented, with early adoption optional. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In September 2015, the FASB issued updated guidance on business combinations accounting requiring the acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Previously, such adjustments were required to be retrospectively recorded in prior period financial information. The amended guidance will be effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The standard is to be applied prospectively, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In November 2015, the FASB issued updated guidance on balance sheet classification of deferred taxes, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities’ processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company elected to early adopt this guidance on a retrospective basis effective December 31, 2014. As a result of the retrospective adoption, the Company reclassified $656 from current deferred tax assets to non-current deferred tax liabilities in the 2014 balance sheet. The adoption of this guidance had no impact on net income (loss). In February 2016, the FASB issued updated guidance on leases which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. We are currently evaluating the effects of the adoption and have not yet determined the impact the revised guidance will have on our consolidated financial statements and related disclosures.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	3. Acquisitions Tea Leaves Health, LLC In August 2015, the Company acquired 100% of the limited liability company membership interests of Tea Leaves Health, LLC (“Tea Leaves”), a provider of a SaaS-based marketing and analytics platform for hospital systems to identify and engage consumers and physicians. The purchase price was valued at $29,893, consisting of (i) $15,000 in cash paid at closing, (ii) 327,784 shares of the Company’s common stock valued at $3,893, issued at closing and held in escrow for potential post-closing working capital and/or indemnification claims, and (iii) $11,000 to be paid within six months of closing in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, in the Company’s sole discretion. The $11,000 deferred purchase price is included in other current liabilities in the accompanying balance sheet as of December 31, 2015 (see Note 17 for further discussion). As a result of a $184 working capital adjustment during the fourth quarter of 2015, the fair value of the total consideration amounts to $29,709. The working capital adjustment was settled via cancellation of 18,251 shares of the Company’s common shares held in escrow. In addition to the purchase price, the former members of Tea Leaves are eligible to receive an additional $20,000 (50% in cash and 50% in shares of the Company’s common stock) based on the achievement of a specified Tea Leaves financial target as of December 31, 2016, as set forth in the Membership Interest Purchase Agreement between the Company, Tea Leaves and the other parties thereto. This earn-out payment is contingent upon the continued employment with the Company of certain former members of Tea Leaves through December 31, 2016, with the earn-out, if earned, to be paid in the first quarter of 2017. See Note 17 for certain amendments to the earn-out terms agreed to in February 2016. For the year ended December 31, 2015, the Company accrued $5,882 in compensation expense for this earn-out, which is reflected in other long-term liabilities in the accompanying balance sheet as of December 31, 2015. Of the $5,882 accrued earn-out, $1,177 is included in sales and marketing expense, $4,117 is included in product development expense and $588 is included in general and administrative expense in the accompanying consolidated statement of operations for the year ended December 31, 2015. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on the respective fair values. The results of operations of Tea Leaves, which are not material for the year ended December 31, 2015, have been included in the consolidated financial statements of the Company from August 6, 2015, the closing date of the acquisition. Pro forma consolidated results of operations giving effect to this acquisition would not vary materially from historical results. The following table summarizes the allocation of the assets acquired and liabilities assumed based on their fair values on the acquisition date. The fair values presented are subject to adjustment during a measurement period of up to one year from the acquisition date. The measurement period provides the Company with the ability to adjust the fair values of acquired assets for new information that is obtained about circumstances that existed as of the acquisition date. Cash and cash equivalents $ 296 Accounts receivable 778 Other current assets 19 Property and equipment 3,404 Intangible assets 3,410 Goodwill 23,330 Deferred revenue (535 ) Accounts payable and accrued expenses (993 ) Total consideration paid $ 29,709 Goodwill recognized as a result of the Tea Leaves acquisition is primarily attributable to expected synergies from enabling the Company to offer an integrated suite of software and media solutions that will allow hospital systems to target both consumers and physicians. All of the goodwill is expected to be deductible for tax purposes. Cambridge BioMarketing Group, LLC In March 2015, the Company acquired 100% of the limited liability company membership interests of Cambridge BioMarketing Group, LLC (“Cambridge”), a provider of strategic launch and marketing solutions for orphan and rare disease products, for a total purchase price of $32,273, of which $24,273 was paid in cash at closing. The remaining $8,000 obligation at closing was comprised of convertible notes that could either convert into shares of the Company’s common stock or be paid in cash at the discretion of the Company. The Company paid the $8,000 obligation in cash in May 2015. As a result of $216 working capital and other purchase price adjustments, the fair value of the total consideration amounts to $32,057. In addition to the purchase price described above, the former members of Cambridge are eligible to receive up to an additional $5,000 in cash based on Cambridge’s achievement of certain revenue and Adjusted EBITDA targets for 2015. This earn-out payment is contingent upon the continued employment with the Company of certain former members of Cambridge at the time the earn-out payment is due to be paid in the first quarter of 2016. The Company records any such earn-out as compensation expense for the applicable period. During the year ended December 31, 2015, the Company accrued $4,913 in compensation expense for this earn-out, which is reflected in accounts payable and accrued expenses in the accompanying balance sheet as of December 31, 2015 and included in sales and marketing expense in the accompanying consolidated statements of operations. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on the respective fair values. The results of operations of Cambridge have been included in the consolidated financial statements of the Company from March 20, 2015, the closing date of the acquisition. The consolidated statement of operations for the year ended December 31, 2015 includes revenue of $20,736 and pre-tax income of $4,651 attributable to Cambridge. Additionally, for the year ended December 31, 2015, acquisition-related costs of $186 are included in general and administrative expenses in the accompanying consolidated statements of operations. The following table summarizes the allocation of the assets acquired and liabilities assumed based on their fair values on the acquisition date. The fair values presented are subject to adjustment during a measurement period of up to one year from the acquisition date. The measurement period provides the Company with the ability to adjust the fair values of acquired assets for new information that is obtained about circumstances that existed as of the acquisition date. Accounts receivable $ 4,406 Other current assets 137 Property and equipment 783 Goodwill 15,360 Intangible assets 14,280 Accounts payable and accrued expenses (2,659 ) Deferred revenue (197 ) Other current liabilities (53 ) Total consideration paid $ 32,057 Goodwill recognized as a result of the Cambridge acquisition is primarily attributable to expected synergies from broadening the Company’s strategic marketing and communications solutions to pharmaceutical brands targeting orphan and rare diseases. All of the goodwill is expected to be deductible for tax purposes. The following table presents the Company’s unaudited pro forma consolidated results for the years ended December 31, 2015 and 2014. The unaudited pro forma results include the historical consolidated statements of operations of the Company and Cambridge, giving effect to the Cambridge acquisition as if it had occurred on January 1, 2014. Unaudited Pro Forma Results Year Ended December 31, 2015 2014 Revenues $ 238,858 $ 203,143 Net income (loss) $ (11,042 ) $ 13,119 The unaudited pro forma results give effect to pro forma events that are directly attributable to the assumed acquisitions, factually supportable, and expected to have a continuing impact on the combined results. The unaudited pro forma results include adjustments primarily related to amortization expense associated with acquired intangible assets, incremental interest expense related to additional borrowings on the Company’s Credit Facility used to fund the Cambridge acquisition and deferred tax expense from amortization of indefinite-lived intangible assets (see Note 12). The unaudited pro forma results are not necessarily indicative of or intended to represent the results that would have been achieved had the transaction been consummated as of the date indicated or that may be achieved in future periods. The actual results reported by the combined company in periods following the acquisition may differ significantly from those reflected in the pro forma results for a number of reasons, including cost saving synergies from operating efficiencies and the effect of the incremental costs incurred to integrate the two companies. DoctorDirectory.com, Inc. In November 2014, the Company acquired all of the outstanding equity of DoctorDirectory.com, Inc. (“DD”), which provided pharmaceutical companies with multi-channel interactive marketing services that target healthcare professionals, for a cash purchase price of $65,000. The DD acquisition enabled the Company to significantly increase the number of healthcare professionals it reaches, deepen and broaden its relationships with pharmaceutical companies, gain valuable expertise across sales, marketing and data and analytics, and introduce new products and services to healthcare professionals. Goodwill recognized from the DD acquisition is primarily attributable to these synergies. None of the goodwill is expected to be deductible for tax purposes. As of December 31, 2014, all purchase price obligations were settled other than $474 of working capital adjustments which were settled during 2015. For the years ended December 31, 2015 and 2014, acquisition-related costs of $21 and $183 are included in general and administrative expenses in the accompanying consolidated statements of operations. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed on the basis of their respective fair values. The results of operations of DD have been included in the consolidated financial statements of the Company from November 12, 2014, the closing date of the acquisition. The following table summarizes the tangible and intangible assets acquired, the liabilities assumed and the consideration paid:. Accounts receivable $ 6,513 Deferred tax asset 81 Other current assets 232 Property and equipment 1,612 Goodwill 44,428 Intangible assets 24,970 Accounts payable and accrued expenses (1,659 ) Deferred tax liability (10,703 ) Total consideration paid $ 65,474 The following table presents the Company’s unaudited pro forma consolidated results for the years ended December 31, 2014 and 2013. The unaudited pro forma results include the historical consolidated statements of operations of the Company and DD, giving effect to the DD acquisition, and related financing transactions, as if they had occurred at January 1, 2013. Unaudited 2014 2013 Revenues $ 201,335 $ 172,877 Net income (loss) $ 4,640 $ (12,425 ) The unaudited pro forma results include: (i) amortization expense associated with acquired intangible and technology assets; (ii) incremental interest expense related to additional borrowings on the Company’s Credit Facility used to fund the DD acquisition, and amortization of related deferred financing costs (see Note 9); (iii) elimination of stock-based compensation expenses related to the pre-acquisition period; (iv) elimination of transaction costs incurred related to the acquisition; and (v) elimination of DD’s historical federal tax provision for the year ended December 31, 2013, as the combined entity would have a loss before provision for income taxes for the year. Additionally, the unaudited pro forma combined net income for the year ended December 31, 2014 includes a pro forma adjustment to eliminate a one-time benefit recorded to the provision for income taxes of $10,033 (see Note 12) which resulted from reducing the deferred tax valuation allowance related to acquired intangible and other assets. The benefit is excluded from the unaudited pro forma results as it will not have a continuing impact on the combined results. The unaudited pro forma results give effect to pro forma events that are (1) directly attributable to the assumed acquisition, (2) factually supportable, and (3) with respect to the combined statements of operations, expected to have a continuing impact on the combined results. Additionally, the unaudited pro forma adjustments are not necessarily indicative of or intended to represent the results that would have been achieved had the transaction been consummated as of the date indicated or that may be achieved in the future. The actual results reported by the combined company in periods following the acquisition may differ significantly from those reflected in the pro forma results for a number of reasons, including cost saving synergies from operating efficiencies and the effect of the incremental costs incurred to integrate the two companies. EQAL, Inc. In September 2012, the Company acquired all of the outstanding equity of EQAL, Inc. (“EQ”), which managed digital media properties for various brands and celebrities. The former stockholders and founders of EQ were eligible to receive up to $5,000 based on the Company’s achievement of certain revenue and operating income targets during 2013. The Company records any such earn-outs as compensation expense for the applicable periods. For the year ended December 31, 2013, the Company incurred $2,211 of such expense, which is included in sales and marketing expense in the accompanying consolidated statements of operations. The earn-out payment, which was payable in cash and shares of the Company’s common stock, was settled in full during the year ended December 31, 2014.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	4. Discontinued Operations In November 2013, the Board of Directors approved a plan to sell the Doctor Solutions business, which provided local online directories, search engine marketing and other marketing services to healthcare professionals. By the end of 2013, the Company identified a buyer and completed the sale, at a price of $1,000. The sale represented a disposal of a component of an entity whose operations and cash flows were eliminated from the Company’s ongoing business after the sale. As such, the operating results, along with the loss on sale, have been reported as discontinued operations in the consolidated statements of operations for the year ended December 31, 2013. As the sale was completed during 2013, there were no results from discontinued operations to report for the years ended December 31, 2015 and 2014. The loss from discontinued operations was comprised of the following: Year ended Revenues $ 7,116 Loss from operations (3,971 ) Loss on sale (1,268 ) Loss from discontinued operations before tax (5,239 ) Income tax (provision) benefit — Net loss from discontinued operations $ (5,239 ) No benefit for income taxes was provided as the Company recorded a full valuation allowance against the NOLs generated by the discontinued operations.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, 2015 2014 Prepaid royalties $ 689 $ 1,225 Prepaid marketing 838 422 Other 3,135 3,882 Total $ 4,662 $ 5,529

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consist of the following: December 31, 2015 2014 Computer equipment and purchased software $ 14,958 $ 12,402 Internally developed software 43,469 37,226 Acquired technology 5,097 1,957 Furniture, fixtures and office equipment 3,761 2,978 Leasehold improvements 7,007 6,381 Website development costs 29,964 25,292 104,256 86,236 Less accumulated depreciation and amortization (75,691 ) (60,734 ) Total $ 28,565 $ 25,502 During the years ended December 31, 2015, 2014 and 2013, the Company capitalized $7,774, $8,870 and $7,416, respectively, of internally developed software costs. Unamortized internally developed software was $12,228 and $13,078 as of December 31, 2015 and 2014, respectively. Amortization expense of internally developed software was $7,092, $6,583 and $5,198 for the years ended December 31, 2015, 2014 and 2013, respectively. Depreciation and amortization expense related to property and equipment is classified as follows in the accompanying consolidated statements of operations: Year Ended December 31, 2015 2014 2013 Sales and marketing $ 1,190 $ 1,286 $ 1,183 Product development 12,764 10,811 10,325 General and administrative 324 327 350 Total depreciation and amortization $ 14,278 $ 12,424 $ 11,858

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	7. Goodwill and Other Intangible Assets During the year ended December 31, 2015, goodwill of $38,690 and definite-lived intangible assets of $17,690 were recorded in connection with the Cambridge and Tea Leaves acquisitions (see Note 3). The value of the intangible assets acquired in connection with the Cambridge acquisition consists of customer relationships of $8,810 and trade names of $5,470, each of which has an estimated useful life of 10 years. The value of the intangible assets acquired in connection with the Tea Leaves acquisition consists of customer relationships of $2,510 and trade names of $900, which have estimated useful lives of 10 years and 3 years, respectively. Additionally, goodwill decreased by $534 and definite-lived intangible assets increased by $1,470 during the year ended December 31, 2015 from working capital adjustments and a revision to the preliminary fair value allocation of assets acquired and liabilities assumed related to the November 2014 DD acquisition (see Note 3 and discussion below). During the year ended December 31, 2014, goodwill of $44,962 and definite-lived intangible assets of $23,500 were recorded in connection with the DD acquisition (see Note 3). Included in the goodwill is $10,033 recorded in connection with a deferred tax liability recognized upon acquisition, related to basis differences in acquired intangible assets (see Note 12). Intangible assets consist of the following: December 31, 2015 December 31, 2014 Gross Accumulated Net Weighted- Gross Accumulated Net Weighted- Customer relationships $ 40,090 $ (14,206 ) $ 25,884 8.9 $ 27,300 $ (11,247 ) $ 16,053 9.5 Trade names 24,985 (7,123 ) 17,862 6.4 18,615 (4,370 ) 14,245 6.5 Other intangibles 3,900 (3,900 ) - 0.0 3,900 (3,482 ) 418 0.7 Total $ 68,975 $ (25,229 ) $ 43,746 $ 49,815 $ (19,099 ) $ 30,716 (a) The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period. Amortization expense relating to the definite-lived intangible assets totaled $6,130, $2,519 and $3,592 for the years ended December 31, 2015, 2014 and 2013, respectively, and is included in general and administrative expense in the accompanying consolidated statements of operations. Future amortization expense of the intangible assets is estimated to be as follows: Year ending December 31: 2016 $ 6,071 2017 6,063 2018 5,755 2019 5,574 2020 5,552 Thereafter 14,731 Total $ 43,746

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	8. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following: December 31, 2015 2014 Accounts payable $ 12,638 $ 8,563 Accrued compensation 4,676 8,260 Accrued acquisition earn-outs 6,338 1,425 Accrued royalties 6,184 5,991 Accrued media and licensed content 3,583 3,716 Accrued interest 1,275 408 Accrued professional fees 623 718 Other accrued expenses 3,246 2,641 Total $ 38,563 $ 31,722

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt The Company entered into a credit facility agreement with a syndicated bank group in March 2014, which replaced its then-existing credit facility. The new credit facility consisted of a revolver (“Revolver”) with a maximum borrowing limit of $35,000 and a term loan (“Term Loan”) of $40,000. In November 2014, in connection with an acquisition, the credit facility was amended and restated to, among other things, (i) increase the maximum borrowing limit of the Revolver from $35,000 to $55,000; (ii) increase the Term Loan from $39,000 outstanding as of such date to $60,000; (iii) extend the maturity date of the Term Loan and the due date of principal on the Revolver from March 2019 to November 2019; and (iv) effect certain modifications to the covenants and terms set forth in the credit facility agreement. In March 2015, the amended and restated credit facility was further amended twice to, among other things, (i) consent to the acquisition of Cambridge, (ii) increase the Term Loan from $59,250 outstanding as of such date to $67,750; (iii) increase the maximum borrowing limit of the Revolver from $55,000 to $82,250; and (iv) effect certain modifications to the covenants and terms set forth in the credit facility agreement. All other materials terms of the credit facility, including the applicable maturity dates, remained unchanged by the March 2015 amendments. In August 2015, the Company entered into a third amendment to the amended and restated credit facility (as amended, the “Credit Facility”) to modify a certain defined term; however, all other material terms and conditions of the Credit Facility remained unchanged by the August 2015 amendment. See Note 17 for certain amendments to the Credit Facility completed in February 2016. The repayment terms of the Revolver provide for quarterly interest payments, with the principal being due in full in November 2019. The repayment terms of the Term Loan provide for quarterly interest and principal payments, with a maturity date of November 2019. The interest rate on the Credit Facility is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on the Company’s consolidated leverage ratio, as defined in the Credit Facility agreement, and there is a 0.50% commitment fee on the unused portion of the Revolver. As of December 31, 2015, the interest rate on the Credit Facility was 4.33%. As of December 31, 2015, there was $66,056 outstanding on the Term Loan and $45,000 outstanding on the Revolver, with $37,250 available to be drawn on the Revolver. The Credit Facility contains certain financial and operational covenants, including requirements to maintain a minimum consolidated fixed charge coverage ratio and a maximum consolidated leverage ratio, each as defined in the Credit Facility agreement, as well as restrictions on certain types of dispositions, mergers and acquisitions, indebtedness, investments, liens and capital expenditures, issuance of capital stock and the Company’s ability to pay dividends. The Credit Facility is secured by a first priority security interest in substantially all of the Company’s existing and future assets. The Company was in compliance with the financial and operational covenants of the Credit Facility as of December 31, 2015 and 2014. Maturities of debt outstanding as of December 31, 2015 are as follows: 2016 $ 6,775 2017 6,775 2018 6,775 2019 90,731 Total $ 111,056 In connection with the credit facility financing in March 2014 discussed above, the Company repaid all outstanding borrowings under its former credit facilities, and such credit facilities were terminated. In March 2014, the Company wrote-off unamortized deferred financing costs of $2,845 and prepayment fees of $1,016 related to the former credit facilities, which is reflected in other expense in the accompanying consolidated statement of operations for the year ended December 31, 2014. As of December 31, 2014, the interest rate on the Credit Facility was 3.48%. As of December 31, 2014, there was $60,000 outstanding on the term loan and $30,000 outstanding on the revolver portion of the Credit Facility. Prior to the credit facility financing in March 2014, the Company maintained a former credit facility, which was entered into in September 2010 and was amended in 2011, 2012 and 2013. This former credit facility (as amended, the “Former Credit Facility”) consisted of a revolving facility and a term loan. Under the Former Credit Facility, the maximum amount that could be outstanding under the revolver was the lesser of $30,000 and 80% of eligible accounts receivable. The maximum amount that could be outstanding under the term loan was $8,500. The repayment terms of the revolver, as amended, provided for monthly interest payments, with the principal being due in September 2015. The repayment terms for the term loan, as amended, provided for monthly interest payments, with principal payments commencing in April 2011 and ending in December 2014. In connection with the credit facilities that were in place prior to 2014, the Company issued to the lenders warrants to purchase a total of: (i) 592,501 shares of common stock at $0.015 per share, (ii) 112,959 shares of Series F redeemable convertible preferred stock at $7.61 per share, and (iii) 110,018 shares of Series C redeemable convertible preferred stock at $3.27 per share. Each of the above warrants were immediately exercisable and, accordingly, the Company calculated the fair value of the warrants using the Black-Scholes option pricing model and recorded deferred financing costs related to the issuances of the warrants in the respective periods. In April 2014, in connection with the closing of the Company’s IPO, the above warrants to purchase 222,977 shares of preferred stock were converted into warrants to purchase an aggregate of 148,650 shares of common stock. This conversion resulted in the warrant liability of $1,140 being reclassified to additional paid-in capital. The Company incurred financing costs of $792, $2,899 and $68 during the years ended December 31, 2015, 2014 and 2013, respectively, which, along with the fair value of warrants, have been deferred and amortized using the effective interest rate method through the final maturities of the respective credit facilities. Deferred financing costs are recorded in other assets in the accompanying consolidated balance sheets. Amortization expense relating to the deferred financing costs was $540, $528 and $1,646 for the years ended December 31, 2015, 2014 and 2013, respectively, and is included in interest expense in the accompanying consolidated statements of operations.

Common Stock and Preferred Stoc

Common Stock and Preferred Stock	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Common Stock and Preferred Stock	10. Common Stock and Preferred Stock As of December 31, 2015 and 2014, there were no shares of preferred stock issued and outstanding. The redeemable convertible preferred stock, Series A-G (collectively, the “Preferred Stock”), which was outstanding at the time of the Company’s IPO, fully converted to common stock in connection with the IPO (see Note 1). Such Preferred Stock had the following characteristics: Conversion Each share of Preferred Stock was convertible at the option of the holder, at any time, into such number of fully paid shares of the Company’s common stock equal to the applicable original issue price for such share of Preferred Stock divided by the applicable conversion price for such share of Preferred Stock then in effect. As of December 31, 2013, the original issue prices and the conversion prices for each series of Preferred Stock were as follows: $0.50 for Series A, $1.77 for Series B, $3.27 for Series C, $6.87 for Series D, $7.98 for Series E, $7.61 for Series F and $9.00 for Series G (prior to giving effect to a 1-for-1.5 reverse stock split of the Company’s common stock implemented on March 14, 2014 in connection with the IPO). The conversion prices for each series of Preferred Stock were subject to adjustment upon the occurrence of certain events, including stock dividends, stock splits, combinations or other similar recapitalizations, and issuance of capital stock at a price below the conversion price in effect for such series of redeemable convertible preferred stock. The conversion price for the Series G convertible preferred stock was also subject to further adjustment in the event of an IPO with a public offering price of less than $11.88 per share. The Company recorded its Preferred Stock outside of permanent equity because the redemption feature was not solely within the control of the Company. In March 2014, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation effecting a 1-for-1.5 reverse stock split of the Company’s issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements and related notes thereto have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on March 14, 2014. In April 2014, in connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware that amended and restated in its entirety the Company’s certificate of incorporation to, among other things, increase the total number of shares of the Company’s common stock that the Company is authorized to issue to 90,000,000, eliminate all references to the various series of preferred stock that were previously authorized (including certain protective measures held by the various series of preferred stock), and to authorize up to 10,000,000 shares of undesignated preferred stock that may be issued from time to time with terms to be set by the Company’s Board of Directors, which rights could be senior to those of the Company’s common stock. In connection with the IPO, all of the Company’s redeemable convertible preferred stock converted into common shares. There was no redeemable convertible preferred stock outstanding at December 31, 2015 or 2014. Conversion of the Redeemable Convertible Preferred Stock In connection with the March 14, 2014 1-for-1.5 reverse stock split, the conversion prices for each series of redeemable convertible preferred stock were subject to a 1-for-1.5 adjustment. As a result, upon the closing of the IPO, the 23,647,834 outstanding shares of Series A, Series B, Series C, Series D, Series E and Series F redeemable convertible preferred stock converted into a total of 15,765,223 shares of common stock. Based on this 1-for-1.5 adjustment, the conversion price for the IPO adjustment specific to the Series G shares increased from $11.88 per share to $17.82 per share. Based on the public offering price of $14.00 per share, the 3,172,436 outstanding shares of Series G convertible preferred stock converted into a total of 2,692,012 shares of common stock, including an additional 577,055 shares of common stock issued as a result of the specific Series G IPO adjustment feature or “ratchet provision.” The ratchet provision, which is treated as a deemed stock dividend for accounting purposes, was calculated as the difference between the number of shares of common stock each holder of Series G would receive upon the automatic conversion of the Series G shares and the number of shares contingently issuable just prior to the automatic conversion based on the initial conversion price multiplied by the IPO price of $14.00 per share, which represents the fair value of the common stock on the date of conversion. In April 2014, the Company recorded a one-time $8,079 non-cash preferred stock deemed dividend related to the issuance of additional common shares resulting from the ratchet provision. Such non-cash preferred stock deemed dividend results in a decrease to net income to arrive at net income attributable to common stockholders and, consequently, results in an adjustment to the Company’s computation of net income per share attributable to common stockholders. Issuance of Common Stock Warrant In March 2014, the Company issued to one of its website partners a warrant to purchase 100,000 shares of common stock at $0.015 per share, in connection with the website partner agreeing to extend the advertising representation agreement by two years. The warrant was immediately exercisable and, accordingly, the Company calculated the fair value of the warrant using the Black-Scholes option pricing model and recorded $1,131 of deferred costs related to the issuance during the year ended December 31, 2014, which is amortized to the Company’s operating results over the life of the agreement. This warrant was exercised during the year ended December 31, 2015. Authorized Capital As of December 31, 2015, the Company was authorized to issue 90,000,000 shares of its common stock and 10,000,000 shares of its preferred stock. As of December 31, 2015, the Company has reserved for issuance 422,478 shares under its 2014 Equity Incentive Plan and 405,084 shares for future issuance under the ESPP.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation The Company has granted non-statutory stock options to employees, directors and consultants of the Company pursuant to its 2003 Stock Option Plan, as amended (the “2003 Plan”), and 2014 Equity Incentive Plan (the “2014 Plan”), which became effective immediately upon the signing of the underwriting agreement related to the IPO in March 2014. Upon the effectiveness of the 2014 Plan, no additional equity awards have been or will be granted under the 2003 Plan. The 2014 Plan provides for the grant of stock options, restricted stock units, and other awards based on the Company’s common stock. The aggregate number of shares of the Company’s common stock that may be issued pursuant to the 2014 Plan is the sum of (1) 200,000 shares, (2) the 388,781 shares reserved for issuance under the 2003 Plan at the time the 2014 Plan became effective, and (3) any shares subject to outstanding stock options that would otherwise have returned to the 2003 Plan (such as upon the expiration or termination of stock options prior to vesting). In addition, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year from January 1, 2015 through January 1, 2024 by the lesser of (a) 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year and (b) a number of shares determined by the Board of Directors. As of December 31, 2015, 422,478 shares have been reserved for future issuance under the 2014 Plan. Stock Options Under the 2014 Plan, stock options are granted at prices not less than the estimated fair market value of the Company’s common stock on the date of grant. The options generally vest and become exercisable over four years from the date of grant and expire after ten years. The following table summarizes stock option activity for the years ended December 31, 2015, 2014 and 2013: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 5,271,707 $ 7.28 7.01 $ 10,556 Granted 901,476 9.41 Exercised (183,501 ) 4.31 Cancelled (531,891 ) 7.67 Outstanding at December 31, 2013 5,457,791 7.61 6.54 20,396 Granted (1) 1,945,851 14.67 Exercised (1,139,891 ) 6.41 Cancelled (370,053 ) 10.52 Outstanding at December 31, 2014 5,893,698 9.94 6.48 29,249 Granted 939,165 12.03 Exercised (358,077 ) 7.23 Cancelled (482,841 ) 12.81 Outstanding at December 31, 2015 5,991,945 10.21 5.30 442 Exercisable at December 31, 2015 4,215,575 9.05 4.16 442 (1) The Company granted 112,500 performance-based options in 2014 where such options vested and became exercisable over approximately nine months from the date of grant, dependent upon the Company meeting certain performance criteria. The performance criteria for these options were met at less than target, which resulted in the vesting of 90,555 of such 112,500 shares on December 31, 2014. The remaining 21,945 shares were cancelled on December 31, 2014. The total intrinsic value of the options exercised during the years ended December 31, 2015, 2014 and 2013 was $1,675, $8,080 and $1,146, respectively. Proceeds from the exercise of options were $2,633, $7,939 and $101 for the years ended December 31, 2015, 2014 and 2013, respectively. The weighted-average fair value per share at date of grant for options granted during the years ended December 31, 2015, 2014 and 2013 was $5.33, $7.53 and $4.80, respectively. The fair value of options granted is estimated on the date of grant using the Black-Scholes option pricing model and recognized in expense over the vesting period of the options using the graded attribution method. The following table presents the weighted-average assumptions used to estimate the fair value of options granted in the years ended December 31, 2015, 2014 and 2013: 2015 2014 2013 Volatility 43.36 % 49.28 % 50.32 % Expected life (years) 6.25 6.25 6.25 Risk-free interest rate 1.73 % 1.92 % 1.54 % Dividend yield — — — The expected stock price volatilities are estimated based on historical realized volatilities of comparable publicly traded company stock prices over a period of time commensurate with the expected term of the option award. The expected life represents the period of time for which the options granted are expected to be outstanding. The Company used the simplified method for determining expected life for options qualifying for treatment due to the limited history the Company currently has with option exercise activity. The risk-free interest rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date. Total stock-based compensation expense related to stock options was $5,751, $7,920 and $3,039 (including $0, $0 and $70 from discontinued operations) for the years ended December 31, 2015, 2014 and 2013, respectively. At December 31, 2015, there was approximately $3,804 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.19 years. The total fair value of stock options vested during the years ended December 31, 2015, 2014 and 2013 was $6,123, $4,328 and $3,668, respectively. Restricted Stock Unit Awards The Company’s restricted stock unit awards (“RSUs”) are agreements to issue shares of the Company’s common stock to employees in the future, upon the satisfaction of certain vesting conditions, which cause them to be subject to risk of forfeiture and restrict the awardholder’s ability to sell or otherwise transfer such RSUs until they vest. Generally, the Company’s RSU grants vest over three years from the grant date subject to continued employment on the applicable vesting dates. The following table summarizes the unvested RSU activity for the year ended December 31, 2015: Number of RSUs Weighted Average Outstanding at December 31, 2014 — $ — Granted (1) 882,001 10.80 Vested (279,986 ) 8.27 Cancelled (53,175 ) 11.99 Outstanding at December 31, 2015 548,840 $ 11.97 (1) RSUs granted during the year ended December 31, 2015 include the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria. The Company has adjusted stock-based compensation expense recognized to-date to reflect estimated performance related to these awards. The total grant-date fair value of RSUs vested during the year ended December 31, 2015 was $1,739. The fair value of RSUs granted is recognized in expense over the vesting period using the graded attribution method. Total stock-based compensation expense related to RSUs was $4,845 for the year ended December 31, 2015. As RSUs were issued for the first time in March 2015, there was no activity and no stock-based compensation expense related to RSUs in 2014 or 2013. At December 31, 2015, there was approximately $3,244 of unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.16 years. 2014 Employee Stock Purchase Plan The Company’s directors adopted, and the stockholders subsequently approved, the ESPP. The ESPP, which became effective immediately upon the signing of the underwriting agreement related to the IPO in March 2014, authorized the issuance of 500,000 shares of the Company’s common stock pursuant to purchase rights granted to employees. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year from January 1, 2015 through January 1, 2024 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 400,000 shares and (c) a number determined by the Board of Directors that is less than (a) and (b). Unless otherwise determined by the Board of Directors, common stock will be purchased for participating employees at a price per share equal to the lower of (a) 85% of the fair market value of a share of the common stock on the first date of an offering, or (b) 85% of the fair market value of a share of the common stock on the date of purchase. Generally, all regular employees may participate in the ESPP and may contribute, through payroll deductions, up to 15% of their earnings toward the purchase of common stock under the ESPP. Under the terms of the ESPP, there are defined limitations as to the amount and value of common stock that can be purchased by each employee. For the years ended December 31, 2015 and 2014, employees purchased an aggregate of 271,623 and 138,184 shares, respectively, under the ESPP at a weighted-average price of $7.40 per share and $11.52 per share, respectively. The Company recorded stock-based compensation expense related to the ESPP of $340 and $1,180 for the years ended December 31, 2015 and 2014, respectively. As the ESPP became effective in March 2014, there were no purchases or charges incurred under the ESPP during 2013. As of December 31, 2015, 405,084 shares of common stock were reserved for future issuance under the ESPP.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The (provision) benefit for income taxes from continuing operations consists of the following: 2015 2014 2013 Federal $ (84 ) $ (250 ) $ — State (225 ) (110 ) (95 ) Foreign (43 ) (45 ) (45 ) Total current (352 ) (405 ) (140 ) Federal (741 ) 7,058 (749 ) State (211 ) 2,013 (213 ) Total deferred (952 ) 9,071 (962 ) Total $ (1,304 ) $ 8,666 $ (1,102 ) The current income tax provision for the years ended December 31, 2015 and 2014 consisted of federal minimum tax and state, local and foreign income taxes, while the current income tax provision for the year ended December 31, 2013 consisted of state, local and foreign income taxes. For the year ended December 31, 2015, the deferred income tax expense includes a deferred tax charge relating to the basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax assets since its reversal is considered indefinite in nature, partially offset by a one-time tax benefit of $601 related to the release of a valuation allowance from finalizing the purchase price valuation of a November 2014 acquisition. For the year ended December 31, 2014, the deferred income tax benefit includes a one-time tax benefit of $10,033 associated with the re-measurement of the valuation allowances against the Company’s deferred tax assets related to the DD acquisition, partially offset by a deferred tax charge relating to the basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax assets since its reversal is considered indefinite in nature. The significant components of the Company’s deferred tax assets (liabilities) were as follows: December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 39,478 $ 40,899 Allowance for doubtful accounts 372 258 Intangible and other assets 1,912 1,595 Deferred revenue 158 190 Stock-based compensation 11,129 9,504 Accrued expenses and other 5,893 4,038 AMT credit 334 250 Depreciation 372 1,722 Total deferred tax assets 59,648 58,456 Valuation allowance (51,185 ) (46,577 ) Net deferred tax assets 8,463 11,879 Deferred tax liabilities: Depreciation — (69 ) Goodwill (5,452 ) (6,028 ) Intangible and other assets (10,581 ) (11,799 ) Total deferred tax liabilities (16,033 ) (17,896 ) Net deferred tax liabilities $ (7,570 ) $ (6,017 ) The Company has provided a valuation allowance against its net deferred tax assets to the extent that it has determined that its deferred tax assets are not “more likely than not” to be realized. In determining realizability, the Company considered various factors including historical profitability and reversing temporary differences, exclusive of indefinite-lived intangibles. The Company’s net deferred tax liabilities increased by $1,553 in 2015 due primarily to basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax assets since its reversal is considered indefinite in nature. At December 31, 2015, the Company had approximately $104,042 of U.S. federal and state net operating loss (“NOL”) carryforwards available to offset future taxable income. The U.S. federal NOL carryforwards will begin to expire from 2026 through 2033. The full utilization of these losses in the future is dependent upon the Company’s ability to generate taxable income and may also be limited due to ownership changes, as defined under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. The Company’s NOL carryforwards at December 31, 2015 include $7,517 of income tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting, which will be reflected as a credit to additional paid-in-capital as these NOLs are utilized. The difference between the tax provision computed at the statutory rate and the tax provision recorded by the Company primarily relates to the change in valuation allowance and state and foreign income taxes on its taxable income. A reconciliation between the statutory rate and the effective tax rate for the years ended December 31, 2015, 2014 and 2013 is as follows: Year Ended December 31, 2015 2014 2013 (Provision) benefit at statutory rate $ 3,618 $ (1,406 ) $ 4,163 Permanent items (467 ) (885 ) (311 ) State taxes (283 ) 1,228 (210 ) Changes in valuation allowance (4,172 ) 9,729 (4,744 ) Total (provision) benefit $ (1,304 ) $ 8,666 $ (1,102 ) The Company has adopted a policy that it will recognize both accrued interest and penalties related to unrecognized benefits in income tax expense, when and if recorded. No material amount of interest or penalties have been recognized since adoption. As of December 31, 2015, 2014 and 2013, there were no unrecognized tax benefits. The Company is subject to taxation in the U.S. and various state, local and foreign jurisdictions. In April 2015, an audit of the Company’s U.S. Federal tax returns for the years ended December 31, 2011 and 2012 was concluded, with no changes or assessments. As of December 31, 2015, none of the Company’s other tax returns have been examined by any income taxing authority. The Company is not subject to U.S. federal, state or non-U.S. income tax examinations by tax authorities for the years prior to 2013. However, to the extent U.S. federal and state NOL carryforwards are utilized, the use of NOLs could be subject to examination by the tax authorities. The Company believes that it has appropriate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on assessment of many factors, including past experience and interpretations of tax law. The Company regularly assesses the adequacy of its income tax contingencies in accordance with ASC 740. As a result, the Company may adjust its income tax contingency liabilities for the impact of new facts and developments, such as changes in interpretations of relevant tax law and assessments from taxing authorities.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Operating Leases The Company is a party to certain non-cancellable operating leases for office space. The future minimum lease commitments for these leases, which expire on various dates through 2023, net of related aggregate sublease rentals, are as follows as of December 31, 2015: 2016 $ 5,078 2017 4,685 2018 3,638 2019 3,529 2020 3,689 Thereafter 11,366 Sublease rentals (1,146 ) Net lease commitments $ 30,839 Rent expense was approximately $4,496, $3,625 and $3,377, net of sublease income of $922, $427 and $102, for the years ended December 31, 2015, 2014 and 2013, respectively. Minimum Guaranteed Royalty Payments The Company has entered into certain agreements with website partners, pursuant to which the Company is required to pay minimum guaranteed royalty payments over the term of the agreement, regardless of revenue generated by the Company. Future minimum guaranteed royalty payments as of December 31, 2015, are as follows: 2016 $ 14,926 2017 12,257 2018 12,135 2019 12,322 2020 12,889 Thereafter 10,000 Total $ 74,529 Certain minimum guaranteed royalty payments with respect to these agreements are subject to reductions if specified performance metrics are not maintained by the other party. Contingency The Company is subject to certain claims that have arisen in the ordinary conduct of business. Based on the advice of counsel and an assessment of the nature and status of any potential claim, and taking into account any accruals the Company may have established for them, the Company currently believes that any liabilities ultimately resulting from such claims will not, individually or in the aggregate, have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Benefit Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Benefit Plan	14. Benefit Plan The Company sponsors a defined contribution 401(k) plan covering all eligible employees, which is subject to the provisions of the Employee Retirement Income Security Act of 1974. Participants of the plan may make annual contributions up to the applicable IRS limit. The Company matches contributions to the plan up to certain limits, including contributions related to acquisitions (see Note 3), for which the Company expensed $821, $487 and $409 during the years ended December 31, 2015, 2014 and 2013, respectively.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	15. Related-Party Transactions During the year ended December 31, 2013, a consulting firm wholly-owned by one of the Company’s directors provided sales consulting services to the Company totaling $142.

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	16. Supplemental Disclosure of Cash Flow Information Supplemental information related to the consolidated statements of cash flows is summarized below: Year Ended December 31, 2015 2014 2013 Supplemental disclosure of cash flow information: Interest paid $ 3,850 $ 3,734 $ 6,173 Income taxes paid $ 126 $ 341 $ 73 Supplemental disclosure of non-cash investing and financing activities: Issuance of common stock for acquired business $ 3,677 $ 919 $ 2,921 Warrants issued in connection with credit facilities $ — $ — $ 149 Warrants issued in connection with website partner agreement $ — $ 1,131 $ — Capital lease obligations incurred $ 90 $ 466 $ 879 Due to sellers of acquired business $ 11,000 $ — $ — Amounts due from stock option exercises $ — $ 43 $ 688

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The following matters occurred after December 31, 2015 and prior to the filing of this Form 10-K: Tea Leaves Purchase Agreement Amendment On February 29, 2016, the Company entered into an amendment to the Membership Interest Purchase Agreement between the Company, Tea Leaves and the other parties thereto. This amendment effected certain modifications to the payment terms of the $11,000 deferred portion of the guaranteed consideration and the terms of the potential earn-out payment. With respect to the deferred portion of the guaranteed consideration initially scheduled to paid within six months of closing, the payment schedule was amended as follows: (i) $5,000 was payable, and paid, on February 5, 2016; (ii) $3,000 will be paid on or prior to June 30, 2016; and (iii) the remainder will be paid on or prior to September 30, 2016. In addition, the former members of Tea Leaves are entitled to receive $200 in interest on each of the aforementioned payment dates. If the Company elects to pay the full amount of the remaining payment to the former members on or prior to March 31, 2016, the Company shall pay $50 in lieu of the additional $400 that would have otherwise been due with the June 30, 2016 and September 30, 2016 payments. With respect to the potential earn-out payment, the former members of Tea Leaves will receive $5,000 of the total $20,000 earn-out if the specific financial target is achieved at any time during 2016. The remaining $15,000 of the earn-out remains subject to achievement of the financial target as of December 31, 2016. This $5,000 payment, if earned, will be promptly paid in cash or 50% in cash and 50% in shares of the Company’s common stock, at the Company’s discretion, and is not subject to forfeiture. If the remaining $15,000 portion of the earn-out is achieved as of December 31, 2016, this payment shall be made in the first quarter of 2017 in a combination of cash and shares of the Company’s common stock such that the overall value of the full $20,000 payment is 50% in cash and 50% in shares of the Company’s common stock. Both of these payments are contingent upon the continued employment with the Company of certain former members of Tea Leaves through the respective dates of payment. Credit Facility Amendment On February 26, 2016, the Company entered into an amendment to the Credit Facility, which effected certain modifications to the financial covenants and terms set forth in the Credit Facility. In addition, on March 2, 2016, the Company drew $15,000 under the Revolver portion of the Credit Facility. As of March 2, 2016, there was $64,363 outstanding on the Term Loan and $60,000 outstanding on the Revolver, with $22,250 available to be drawn on the Revolver. Other than the above matters, there were no other significant matters occurring after December 31, 2015 and prior to the filing of this Form 10-K.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	18. Quarterly Financial Data (unaudited) The following tables summarize the quarterly financial data for the years ended December 31, 2015 and 2014: 2015 First Second Third Fourth Revenues Advertising and sponsorship revenues $ 36,338 $ 50,225 $ 49,630 $ 72,900 Premium services revenues 4,836 4,580 4,684 8,798 Total revenues 41,174 54,805 54,314 81,698 Operating expenses: Cost of revenues 14,076 13,926 15,637 23,284 Sales and marketing 12,725 21,041 18,531 22,464 Product development 12,602 12,187 14,163 16,968 General and administrative 9,804 10,065 10,010 9,608 Total operating expenses 49,207 57,219 58,341 72,324 Income (loss) from operations (8,033 ) (2,414 ) (4,027 ) 9,374 Interest expense, net (953 ) (1,426 ) (1,429 ) (1,428 ) Other expense — — — — Income (loss) from operations before (provision) benefit for income taxes (8,986 ) (3,840 ) (5,456 ) 7,946 (Provision) benefit for income taxes 918 5,534 (7,262 ) (494 ) Net income (loss) $ (8,068 ) $ 1,694 $ (12,718 ) $ 7,452 Net income (loss) attributable to common stockholders per common share: Basic $ (0.26 ) $ 0.05 $ (0.40 ) $ 0.23 Diluted $ (0.26 ) $ 0.05 $ (0.40 ) $ 0.23 Weighted-average common shares outstanding: Basic 31,525,559 31,755,107 32,138,214 32,482,159 Diluted 31,525,559 33,373,407 32,138,214 32,904,143 2014 First Second Third Fourth Revenues Advertising and sponsorship revenues $ 32,692 $ 36,882 $ 37,910 $ 58,981 Premium services revenues 4,813 4,565 4,414 4,068 Total revenues 37,505 41,447 42,324 63,049 Operating expenses: Cost of revenues 11,421 10,961 11,006 15,908 Sales and marketing 10,220 12,216 12,213 13,956 Product development 10,762 10,805 10,886 12,088 General and administrative 6,595 7,126 7,504 8,816 Total operating expenses 38,998 41,108 41,609 50,768 Income (loss) from operations (1,493 ) 339 715 12,281 Interest expense, net (1,863 ) (585 ) (500 ) (763 ) Other expense (4,114 ) — — — Income (loss) from continuing operations before benefit (provision) for income taxes (7,470 ) (246 ) 215 11,518 Benefit (provision) for income taxes (289 ) (349 ) (365 ) 9,669 Net income (loss) (7,759 ) (595 ) (150 ) 21,187 Series G preferred stock deemed dividend — (8,079 ) — — Net income (loss) attributable to common stockholders $ (7,759 ) $ (8,674 ) $ (150 ) $ 21,187 Net income (loss) attributable to common stockholders per common share: Basic $ (1.44 ) $ (0.29 ) $ (0.00 ) $ 0.68 Diluted $ (1.44 ) $ (0.29 ) $ (0.00 ) $ 0.64 Weighted-average common shares outstanding: Basic 5,403,846 29,802,970 30,404,529 31,076,588 Diluted 5,403,846 29,802,970 30,404,529 32,977,544

Significant Accounting Polici26

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of the acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, current business factors and other available information. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition and deferred revenue, allowance for doubtful accounts, internal software development costs and website development costs, valuation of long-lived assets, goodwill and other intangible assets, income taxes and stock-based compensation.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior year financial statements to conform to the December 31, 2015 presentation.
Initial Public Offering	Initial Public Offering On April 2, 2014, the Company closed its initial public offering of common stock (“IPO”). The IPO, including the additional shares issued and sold on April 30, 2014 pursuant to the underwriters’ exercise of their over-allotment option, resulted in net proceeds of $70,622, after deducting underwriting discounts and commissions and offering costs borne by the Company totaling $8,848. As a result of the IPO, the Company issued and sold 5,676,414 shares of common stock at a public offering price of $14.00 per share, and all of the Company’s redeemable convertible preferred stock outstanding automatically converted into an aggregate of 18,457,235 shares of common stock, including 577,055 additional shares of common stock related to the Series G redeemable convertible preferred stock ratchet provision (refer to Note 10 for further discussion). In addition, certain selling stockholders exercised stock options and warrants for an aggregate of 339,053 shares of common stock, 149,839 shares of common stock were issued upon the automatic net exercise of a warrant, and outstanding warrants to purchase 222,977 shares of redeemable convertible preferred stock automatically converted into warrants to purchase an aggregate of 148,650 shares of common stock, which resulted in the reclassification of the preferred stock warrant liability of $1,140 to additional paid-in capital.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the lease term or the estimated useful life of the improvement.
Operating Leases	Operating Leases The Company recognizes rent expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term including reasonably assured renewal periods, net of lease incentives, from the time that the Company controls the leased property. Tenant improvement allowances are recognized as a reduction to rent expense on a straight-line basis over the lease term.
Internal Software Development Costs	Internal Software Development Costs The Company incurs costs to develop software for internal use. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of payroll and related benefits, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years.
Website Development Costs	Website Development Costs The Company incurs costs to develop its websites, tools and applications. The Company expenses all costs that relate to the planning and post-implementation phases of website development as product development expense. Costs incurred in the development phase, consisting principally of third-party consultants and related charges, and the costs of content determined to provide a future economic benefit, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years.
Goodwill	Goodwill Goodwill represents the excess cost over fair value of the identifiable net assets of acquired businesses. Goodwill is tested for impairment on an annual basis as of October 1, and whenever events or circumstances indicate that the carrying value of the asset may not be recoverable. An initial qualitative analysis is performed evaluating whether any events and circumstances occurred or exist that provide evidence that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on this analysis, indicators deem it more likely than not that the fair value of the reporting unit is less than its carrying amount, then the two-step quantitative impairment test is performed; otherwise, no further step is required. If and when needed to complete the two-step quantitative assessment, the fair value of goodwill is estimated using a combination of an income approach based on the present value of estimated future cash flows, and a market approach examining transactions in the marketplace involving the sale of stocks of similar publicly traded companies, or the sale of entire companies engaged in operations similar to those of the Company. As the Company has one operating segment and one reporting unit, the first step of the impairment test requires a comparison of the fair value of the reporting unit, or business enterprise value as a whole, to the carrying value of the Company’s invested capital. If the carrying amount exceeds the fair value, there is indication that an impairment may exist, and a second step must be performed. If the carrying amount is less than the fair value, no indication of impairment exists, and a second step is not performed. The evaluation of the Company’s goodwill indicated that the carrying value of the asset was less than the fair value and, accordingly, there was no impairment loss recognized for the years ended December 31, 2015, 2014 and 2013.
Long-Lived Assets	Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with definite lives, for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The intangible assets with definite lives consist principally of trade names and customer relationships. Definite-lived intangible assets are amortized over their estimated useful lives, ranging from three to ten years, using the straight-line method which approximates the pattern in which economic benefits are consumed. In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets and other long-lived assets on an ongoing basis. During the year ended December 31, 2015, an impairment charge of $1,416 was recorded related to certain software development projects which the Company decided not to move forward with. The $1,416 charge is included in product development expense in the accompanying consolidated statements of operations. There were no indicators of impairment of the Company’s long-lived assets during the year ended December 31, 2014. During the year ended December 31, 2013, the Company recorded an impairment charge of $1,190 related to the consolidation and reorganization of certain website content and tools. This $1,190 charge is included in product development expense in the accompanying consolidated statements of operations.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company generates its revenue from (i) advertising and sponsorships and (ii) premium services, including consumer subscriptions, SaaS-based licensing fees and other licensing fees. Advertising revenue is recognized in the period in which the advertisement is delivered. Revenue from sponsorships, which includes time and materials based creative services, is recognized over the period the Company substantially satisfies its contractual obligations as required under the respective sponsorship agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on management’s best estimate of selling price. Subscriptions are generally paid in advance on a monthly, quarterly or annual basis. Subscription revenue, after deducting refunds and charge-backs, is recognized on a straight-line basis ratably over the subscription periods. SaaS and other licensing revenue is generally recognized on a straight-line basis ratably over the life of the contract. Deferred revenue relates to: (i) subscription fees for which amounts have been collected but for which revenue has not been recognized, and (ii) advertising and sponsorship fees and licensing fees billed in advance of when the revenue is to be earned.
Cost of Revenues	Cost of Revenues Cost of revenues consists principally of the expenses associated with aggregating the total audience across the Company’s websites, including (i) royalty expenses for licensing content for certain websites and for the portion of advertising revenue the Company pays to the owners of certain other websites, and (ii) media costs associated with audience aggregation activities. Cost of revenues also includes market research incentives, direct mail marketing and fulfillment costs, as well as out-of-pocket costs related to creative services and costs associated with subscription fees for our premium services, ad serving and other expenses. Royalty expense amounted to $23,805, $20,937 and $18,673 for the years ended December 31, 2015, 2014 and 2013, respectively. Media costs consist primarily of fees paid to online publishers, Internet search companies and other media channels for search engine and database marketing, and display and television advertising. These media activities are attributable to revenue-generating and audience aggregation events, designed to increase the audience to the websites the Company operates, increase the number of subscribers to premium services and grow the Company’s registered user base. Media costs totaled $32,198, $24,973 and $22,437 for the years ended December 31, 2015, 2014 and 2013, respectively.
Other Expense	Other Expense There were no charges reflected as other expense for the years ended December 31, 2015 and 2013. In connection with the refinancing of its credit facilities in 2014, the Company wrote-off unamortized deferred financing costs totaling $2,845 and incurred prepayment fees of $1,016, which, together with the mark-to-market adjustment on certain preferred stock warrants of $253, is reflected as other expense in the accompanying consolidated statements of operations for the year ended December 31, 2014.
Income Taxes	Income Taxes The Company accounts for taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the tax and financial statement reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset. As a result of the Company’s historical operating performance and the cumulative net losses incurred to date, the Company does not have sufficient objective evidence to support the recovery of the net deferred tax assets. Accordingly, the Company has established a valuation allowance against net deferred tax assets for financial reporting purposes to the extent it is determined that such deferred tax assets are not more likely than not to be realized. The Company accounts for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more likely than not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Other than the Series G preferred stock deemed dividend reflected in the accompanying statement of operations for the year end December 31, 2014 (see Note 10), the Company has no items of other comprehensive income (loss).
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short-term maturities, the carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other highly liquid money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of the Company’s debt approximates the recorded amounts as the interest rates on the credit facilities are based on market interest rates.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for all share-based payments, including grants of employee stock options and restricted stock units, based on the fair value of the award measured at the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of the stock option awards and stock purchase rights provided under the 2014 Employee Stock Purchase Plan, or ESPP. The fair value of restricted stock unit awards represents the closing price of the Company’s common stock on the date of grant. Stock-based compensation expense is recognized over the period during which the recipient provides services, generally the vesting period, net of estimated forfeitures.
Business Concentrations, Accounts Receivable and Credit Risk	Business Concentrations, Accounts Receivable and Credit Risk Financial instruments which potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. Cash and cash equivalents includes U.S. Treasury securities and other money market funds. Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the Company’s customer base and the ongoing credit evaluation of its customers. For the years ended December 31, 2015 and 2014, no advertising customer accounted for greater than 10% of total revenues. For the year ended December 31, 2013, one advertising customer accounted for 12% of total revenues. As of December 31, 2015 and 2014, no advertising customers accounted for greater than 10% of total accounts receivable. As many of the Company’s advertising customers work through the same advertising agencies, the Company also monitors the concentration of accounts receivable at the agency level. As of December 31, 2015 and 2014, no advertising agency accounted for greater than 10% of accounts receivable. The Company’s net accounts receivable balance of $90,356 and $68,007 reflected in the accompanying balance sheets as of December 31, 2015 and 2014, respectively, include unbilled accounts receivable of $12,224 and $7,064 as of December 31, 2015 and 2014, respectively, which primarily represent revenue earned and accrued in the respective fiscal years, billed subsequent to year end. An allowance for doubtful accounts is established with respect to accounts receivable that the Company has determined to be doubtful of collection, based upon factors surrounding the credit risk of customers, historical experience and other information. The following table summarizes the activity of the allowance for doubtful accounts: Year Ended December 31, 2015 2014 2013 Balance at beginning of year $ 637 $ 530 $ 651 Bad debt provision 326 384 251 Write-offs (54 ) (277 ) (372 ) Balance at end of year $ 909 $ 637 $ 530
Business Combinations	Business Combinations The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. During the measurement period, which is up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, based on additional information impacting the assigned estimated fair values.
Segment Information	Segment Information The Company and its subsidiaries are organized in a single operating segment, providing digital health marketing and communications solutions, and the Company also has one reportable segment. Substantially all of the Company’s revenues are derived from U.S. sources.
Net Income (Loss) Attributable to Common Stockholders per Common Share	Net Income (Loss) Attributable to Common Stockholders per Common Share Basic net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, adjusted to reflect potentially dilutive securities. Potentially dilutive securities consist of incremental shares issuable upon the assumed exercise of stock options, restricted stock units and warrants using the treasury stock method, convertible preferred shares using the “if converted” method, and employee withholdings to purchase common stock under the Company’s ESPP. Due to the net losses for the years ended December 31, 2015 and 2013, the aforementioned potentially dilutive securities were not included in the computation of diluted net loss per common share because the effect would have been anti-dilutive. The basic and diluted net income (loss) attributable to common stockholders per common share is calculated as follows for the periods presented: Year Ended December 31, 2015 2014 2013 Numerator: Income (loss) from continuing operations $ (11,640 ) $ 12,683 $ (12,997 ) Loss from discontinued operations, net of tax — — (5,239 ) Net income (loss) (11,640 ) 12,683 (18,236 ) Series G preferred stock deemed dividend — (8,079 ) — Net income (loss) attributable to common stockholders $ (11,640 ) $ 4,604 $ (18,236 ) Denominator: Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share 31,977,246 24,259,395 5,103,351 Dilutive securities: Stock option awards — 2,235,059 — Warrants to purchase common stock — 412,305 — Employee stock purchase plan — 5,023 — Total weighted-average diluted shares 31,977,246 26,911,782 5,103,351 Basic net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.19 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.19 $ (3.57 ) Diluted net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.17 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.17 $ (3.57 ) The following securities were outstanding for the periods presented below and have been excluded from the calculation of diluted net income (loss) attributable to common stockholders per common share because the effect is anti-dilutive: Year Ended December 31, 2015 2014 2013 Warrants to purchase common stock 76,659 — 583,247 Warrants to purchase redeemable convertible preferred stock — — 148,650 Redeemable convertible preferred stock — — 17,880,180 Stock option awards 6,252,223 1,337,766 5,366,785 Unvested RSU awards 453,349 — — Employee stock purchase plan 100,722 — — Total weighted-average anti-dilutive securities 6,882,953 1,337,766 23,978,862
Foreign Currency	Foreign Currency The financial statements and transactions of the Company’s foreign subsidiary are maintained in its local currency. The translation of foreign currencies into United States dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date, and for revenue and expense accounts using average exchange rates during the year. Foreign currency gains or losses are included in the consolidated statements of operations and were not material in any of the periods presented.
Recently Issued and Adopted Accounting Standards	Recently Issued and Adopted Accounting Standards In April 2014, the Financial Accounting Standards Board (“FASB”) issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In May 2014, the FASB issued guidance which provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The guidance was originally to be effective for annual and interim periods beginning after December 15, 2016. In August 2015, the FASB approved a one year deferral of the effective date to December 15, 2017 and early adoption is permitted, but not before the original effective date of December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method and is currently evaluating the effect that the new standard will have on the consolidated financial statements and related disclosures. In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In April 2015, the FASB issued updated guidance on the presentation of debt issuance costs in financial statements. The new guidance requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. This guidance will be effective for the Company beginning in the first quarter of 2016 on a retrospective basis for all periods presented, with early adoption optional. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In September 2015, the FASB issued updated guidance on business combinations accounting requiring the acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Previously, such adjustments were required to be retrospectively recorded in prior period financial information. The amended guidance will be effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The standard is to be applied prospectively, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements. In November 2015, the FASB issued updated guidance on balance sheet classification of deferred taxes, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities’ processes as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, with earlier application permitted. The Company elected to early adopt this guidance on a retrospective basis effective December 31, 2014. As a result of the retrospective adoption, the Company reclassified $656 from current deferred tax assets to non-current deferred tax liabilities in the 2014 balance sheet. The adoption of this guidance had no impact on net income (loss). In February 2016, the FASB issued updated guidance on leases which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. We are currently evaluating the effects of the adoption and have not yet determined the impact the revised guidance will have on our consolidated financial statements and related disclosures.

Significant Accounting Polici27

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of allowance for doubtful accounts	Year Ended December 31, 2015 2014 2013 Balance at beginning of year $ 637 $ 530 $ 651 Bad debt provision 326 384 251 Write-offs (54 ) (277 ) (372 ) Balance at end of year $ 909 $ 637 $ 530
Schedule of earnings per share, basic and diluted	Year Ended December 31, 2015 2014 2013 Numerator: Income (loss) from continuing operations $ (11,640 ) $ 12,683 $ (12,997 ) Loss from discontinued operations, net of tax — — (5,239 ) Net income (loss) (11,640 ) 12,683 (18,236 ) Series G preferred stock deemed dividend — (8,079 ) — Net income (loss) attributable to common stockholders $ (11,640 ) $ 4,604 $ (18,236 ) Denominator: Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share 31,977,246 24,259,395 5,103,351 Dilutive securities: Stock option awards — 2,235,059 — Warrants to purchase common stock — 412,305 — Employee stock purchase plan — 5,023 — Total weighted-average diluted shares 31,977,246 26,911,782 5,103,351 Basic net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.19 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.19 $ (3.57 ) Diluted net income (loss) attributable to common stockholders per common share: Income (loss) from continuing operations $ (0.36 ) $ 0.17 $ (2.55 ) Loss from discontinued operations, net of tax — — (1.03 ) Net income (loss) attributable to common stockholders $ (0.36 ) $ 0.17 $ (3.57 )
Schedule of securities excluded from the calculation of diluted net income (loss)	Year Ended December 31, 2015 2014 2013 Warrants to purchase common stock 76,659 — 583,247 Warrants to purchase redeemable convertible preferred stock — — 148,650 Redeemable convertible preferred stock — — 17,880,180 Stock option awards 6,252,223 1,337,766 5,366,785 Unvested RSU awards 453,349 — — Employee stock purchase plan 100,722 — — Total weighted-average anti-dilutive securities 6,882,953 1,337,766 23,978,862

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Tea Leaves Health Llc [Member]
Acquisitions (Tables) [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	Cash and cash equivalents $ 296 Accounts receivable 778 Other current assets 19 Property and equipment 3,404 Intangible assets 3,410 Goodwill 23,330 Deferred revenue (535 ) Accounts payable and accrued expenses (993 ) Total consideration paid $ 29,709
Cambridge Biomarketing Group Llc [Member]
Acquisitions (Tables) [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	Accounts receivable $ 4,406 Other current assets 137 Property and equipment 783 Goodwill 15,360 Intangible assets 14,280 Accounts payable and accrued expenses (2,659 ) Deferred revenue (197 ) Other current liabilities (53 ) Total consideration paid $ 32,057
Schedule of business acquisition, pro forma information	Unaudited Pro Forma Results Year Ended December 31, 2015 2014 Revenues $ 238,858 $ 203,143 Net income (loss) $ (11,042 ) $ 13,119
DD [Member]
Acquisitions (Tables) [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	Accounts receivable $ 6,513 Deferred tax asset 81 Other current assets 232 Property and equipment 1,612 Goodwill 44,428 Intangible assets 24,970 Accounts payable and accrued expenses (1,659 ) Deferred tax liability (10,703 ) Total consideration paid $ 65,474
Schedule of business acquisition, pro forma information	Unaudited 2014 2013 Revenues $ 201,335 $ 172,877 Net income (loss) $ 4,640 $ (12,425 )

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures	Year ended Revenues $ 7,116 Loss from operations (3,971 ) Loss on sale (1,268 ) Loss from discontinued operations before tax (5,239 ) Income tax (provision) benefit — Net loss from discontinued operations $ (5,239 )

Prepaid Expenses and Other Cu30

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid expenses and other current assets	December 31, 2015 2014 Prepaid royalties $ 689 $ 1,225 Prepaid marketing 838 422 Other 3,135 3,882 Total $ 4,662 $ 5,529

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and equipment	December 31, 2015 2014 Computer equipment and purchased software $ 14,958 $ 12,402 Internally developed software 43,469 37,226 Acquired technology 5,097 1,957 Furniture, fixtures and office equipment 3,761 2,978 Leasehold improvements 7,007 6,381 Website development costs 29,964 25,292 104,256 86,236 Less accumulated depreciation and amortization (75,691 ) (60,734 ) Total $ 28,565 $ 25,502
Schedule of Depreciation and amortization expense related to property and equipment	Year Ended December 31, 2015 2014 2013 Sales and marketing $ 1,190 $ 1,286 $ 1,183 Product development 12,764 10,811 10,325 General and administrative 324 327 350 Total depreciation and amortization $ 14,278 $ 12,424 $ 11,858

Goodwill and Other Intangible32

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible assets	December 31, 2015 December 31, 2014 Gross Accumulated Net Weighted- Gross Accumulated Net Weighted- Customer relationships $ 40,090 $ (14,206 ) $ 25,884 8.9 $ 27,300 $ (11,247 ) $ 16,053 9.5 Trade names 24,985 (7,123 ) 17,862 6.4 18,615 (4,370 ) 14,245 6.5 Other intangibles 3,900 (3,900 ) - 0.0 3,900 (3,482 ) 418 0.7 Total $ 68,975 $ (25,229 ) $ 43,746 $ 49,815 $ (19,099 ) $ 30,716 (a) The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period.
Schedule of Future amortization expense of the intangible assets	2016 $ 6,071 2017 6,063 2018 5,755 2019 5,574 2020 5,552 Thereafter 14,731 Total $ 43,746

Accounts Payable and Accrued 33

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts payable and accrued expenses	December 31, 2015 2014 Accounts payable $ 12,638 $ 8,563 Accrued compensation 4,676 8,260 Accrued acquisition earn-outs 6,338 1,425 Accrued royalties 6,184 5,991 Accrued media and licensed content 3,583 3,716 Accrued interest 1,275 408 Accrued professional fees 623 718 Other accrued expenses 3,246 2,641 Total $ 38,563 $ 31,722

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Maturities of debt outstanding	2016 $ 6,775 2017 6,775 2018 6,775 2019 90,731 Total $ 111,056

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2012 5,271,707 $ 7.28 7.01 $ 10,556 Granted 901,476 9.41 Exercised (183,501 ) 4.31 Cancelled (531,891 ) 7.67 Outstanding at December 31, 2013 5,457,791 7.61 6.54 20,396 Granted (1) 1,945,851 14.67 Exercised (1,139,891 ) 6.41 Cancelled (370,053 ) 10.52 Outstanding at December 31, 2014 5,893,698 9.94 6.48 29,249 Granted 939,165 12.03 Exercised (358,077 ) 7.23 Cancelled (482,841 ) 12.81 Outstanding at December 31, 2015 5,991,945 10.21 5.30 442 Exercisable at December 31, 2015 4,215,575 9.05 4.16 442 (1) The Company granted 112,500 performance-based options in 2014 where such options vested and became exercisable over approximately nine months from the date of grant, dependent upon the Company meeting certain performance criteria. The performance criteria for these options were met at less than target, which resulted in the vesting of 90,555 of such 112,500 shares on December 31, 2014. The remaining 21,945 shares were cancelled on December 31, 2014.
Schedule of weighted-average assumptions used to estimate the fair value of options granted	2015 2014 2013 Volatility 43.36 % 49.28 % 50.32 % Expected life (years) 6.25 6.25 6.25 Risk-free interest rate 1.73 % 1.92 % 1.54 % Dividend yield — — —
Schedule of unvested RSU activity	Number of RSUs Weighted Average Outstanding at December 31, 2014 — $ — Granted (1) 882,001 10.80 Vested (279,986 ) 8.27 Cancelled (53,175 ) 11.99 Outstanding at December 31, 2015 548,840 $ 11.97 (1) RSUs granted during the year ended December 31, 2015 include the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria. The Company has adjusted stock-based compensation expense recognized to-date to reflect estimated performance related to these awards.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of income taxes from continuing operations	2015 2014 2013 Federal $ (84 ) $ (250 ) $ — State (225 ) (110 ) (95 ) Foreign (43 ) (45 ) (45 ) Total current (352 ) (405 ) (140 ) Federal (741 ) 7,058 (749 ) State (211 ) 2,013 (213 ) Total deferred (952 ) 9,071 (962 ) Total $ (1,304 ) $ 8,666 $ (1,102 )
Schedule of deferred tax assets liabilities	December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 39,478 $ 40,899 Allowance for doubtful accounts 372 258 Intangible and other assets 1,912 1,595 Deferred revenue 158 190 Stock-based compensation 11,129 9,504 Accrued expenses and other 5,893 4,038 AMT credit 334 250 Depreciation 372 1,722 Total deferred tax assets 59,648 58,456 Valuation allowance (51,185 ) (46,577 ) Net deferred tax assets 8,463 11,879 Deferred tax liabilities: Depreciation — (69 ) Goodwill (5,452 ) (6,028 ) Intangible and other assets (10,581 ) (11,799 ) Total deferred tax liabilities (16,033 ) (17,896 ) Net deferred tax liabilities $ (7,570 ) $ (6,017 )
Schedule of Effective income tax rate reconciliation	Year Ended December 31, 2015 2014 2013 (Provision) benefit at statutory rate $ 3,618 $ (1,406 ) $ 4,163 Permanent items (467 ) (885 ) (311 ) State taxes (283 ) 1,228 (210 ) Changes in valuation allowance (4,172 ) 9,729 (4,744 ) Total (provision) benefit $ (1,304 ) $ 8,666 $ (1,102 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future minimum lease commitments for these leases	2016 $ 5,078 2017 4,685 2018 3,638 2019 3,529 2020 3,689 Thereafter 11,366 Sublease rentals (1,146 ) Net lease commitments $ 30,839
Schedule of Future minimum guaranteed payments	2016 $ 14,926 2017 12,257 2018 12,135 2019 12,322 2020 12,889 Thereafter 10,000 Total $ 74,529

Supplemental Disclosure of Ca38

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental information related to the consolidated statements of cash flows	Year Ended December 31, 2015 2014 2013 Supplemental disclosure of cash flow information: Interest paid $ 3,850 $ 3,734 $ 6,173 Income taxes paid $ 126 $ 341 $ 73 Supplemental disclosure of non-cash investing and financing activities: Issuance of common stock for acquired business $ 3,677 $ 919 $ 2,921 Warrants issued in connection with credit facilities $ — $ — $ 149 Warrants issued in connection with website partner agreement $ — $ 1,131 $ — Capital lease obligations incurred $ 90 $ 466 $ 879 Due to sellers of acquired business $ 11,000 $ — $ — Amounts due from stock option exercises $ — $ 43 $ 688

Quarterly Financial Data (Una39

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial data	2015 First Second Third Fourth Revenues Advertising and sponsorship revenues $ 36,338 $ 50,225 $ 49,630 $ 72,900 Premium services revenues 4,836 4,580 4,684 8,798 Total revenues 41,174 54,805 54,314 81,698 Operating expenses: Cost of revenues 14,076 13,926 15,637 23,284 Sales and marketing 12,725 21,041 18,531 22,464 Product development 12,602 12,187 14,163 16,968 General and administrative 9,804 10,065 10,010 9,608 Total operating expenses 49,207 57,219 58,341 72,324 Income (loss) from operations (8,033 ) (2,414 ) (4,027 ) 9,374 Interest expense, net (953 ) (1,426 ) (1,429 ) (1,428 ) Other expense — — — — Income (loss) from operations before (provision) benefit for income taxes (8,986 ) (3,840 ) (5,456 ) 7,946 (Provision) benefit for income taxes 918 5,534 (7,262 ) (494 ) Net income (loss) $ (8,068 ) $ 1,694 $ (12,718 ) $ 7,452 Net income (loss) attributable to common stockholders per common share: Basic $ (0.26 ) $ 0.05 $ (0.40 ) $ 0.23 Diluted $ (0.26 ) $ 0.05 $ (0.40 ) $ 0.23 Weighted-average common shares outstanding: Basic 31,525,559 31,755,107 32,138,214 32,482,159 Diluted 31,525,559 33,373,407 32,138,214 32,904,143 2014 First Second Third Fourth Revenues Advertising and sponsorship revenues $ 32,692 $ 36,882 $ 37,910 $ 58,981 Premium services revenues 4,813 4,565 4,414 4,068 Total revenues 37,505 41,447 42,324 63,049 Operating expenses: Cost of revenues 11,421 10,961 11,006 15,908 Sales and marketing 10,220 12,216 12,213 13,956 Product development 10,762 10,805 10,886 12,088 General and administrative 6,595 7,126 7,504 8,816 Total operating expenses 38,998 41,108 41,609 50,768 Income (loss) from operations (1,493 ) 339 715 12,281 Interest expense, net (1,863 ) (585 ) (500 ) (763 ) Other expense (4,114 ) — — — Income (loss) from continuing operations before benefit (provision) for income taxes (7,470 ) (246 ) 215 11,518 Benefit (provision) for income taxes (289 ) (349 ) (365 ) 9,669 Net income (loss) (7,759 ) (595 ) (150 ) 21,187 Series G preferred stock deemed dividend — (8,079 ) — — Net income (loss) attributable to common stockholders $ (7,759 ) $ (8,674 ) $ (150 ) $ 21,187 Net income (loss) attributable to common stockholders per common share: Basic $ (1.44 ) $ (0.29 ) $ (0.00 ) $ 0.68 Diluted $ (1.44 ) $ (0.29 ) $ (0.00 ) $ 0.64 Weighted-average common shares outstanding: Basic 5,403,846 29,802,970 30,404,529 31,076,588 Diluted 5,403,846 29,802,970 30,404,529 32,977,544

Significant Accounting Polici40

Significant Accounting Policies - Allowance for doubtful accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at beginning of year	$ 637	$ 530	$ 651
Bad debt provision	326	384	251
Write-offs	(54)	(277)	(372)
Balance at end of year	$ 909	$ 637	$ 530

Significant Accounting Polici41

Significant Accounting Policies - Basic and diluted net income (loss) (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Income (loss) from continuing operations (in Dollars)									$ (11,640)	$ 12,683	$ (12,997)
Loss from discontinued operations, net of tax (in Dollars)											(5,239)
Net income (loss)	$ 7,452	$ (12,718)	$ 1,694	$ (8,068)	$ 21,187	$ (150)	$ (595)	$ (7,759)	(11,640)	12,683	(18,236)
Series G preferred stock deemed dividend							$ (8,079)			(8,079)
Net income (loss) attributable to common stockholders									$ (11,640)	$ 4,604	$ (18,236)
Denominator:
Weighted-average number of common shares outstanding for basic net income (loss) attributable to common stockholders per common share (in Shares)	32,482,159	32,138,214	31,755,107	31,525,559	31,076,588	30,404,529	29,802,970	5,403,846	31,977,246	24,259,395	5,103,351
Dilutive securities:
Stock option awards (in Shares)										2,235,059
Warrants to purchase common stock (in Shares)										412,305
Employee stock purchase plan										5,023
Total weighted-average diluted shares (in Shares)	32,904,143	32,138,214	33,373,407	31,525,559	32,977,544	30,404,529	29,802,970	5,403,846	31,977,246	26,911,782	5,103,351
Basic net income (loss) attributable to common stockholders per common share:
Income (loss) from continuing operations									$ (0.36)	$ 0.19	$ (2.55)
Loss from discontinued operations, net of tax											(1.03)
Net income (loss) attributable to common stockholders	$ 0.23	$ (0.40)	$ 0.05	$ (0.26)	$ 0.68	$ 0	$ (0.29)	$ (1.44)	(0.36)	0.19	(3.57)
Diluted net income (loss) attributable to common stockholders per common share:
Income (loss) from continuing operations									(0.36)	0.17	(2.55)
Loss from discontinued operations, net of tax											(1.03)
Net income (loss) attributable to common stockholders	$ 0.23	$ (0.40)	$ 0.05	$ (0.26)	$ 0.64	$ 0	$ (0.29)	$ (1.44)	$ (0.36)	$ 0.17	$ (3.57)

Significant Accounting Polici42

Significant Accounting Policies - Weighted-average anti-dilutive securities (Details 2) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities	6,882,953	1,337,766	23,978,862
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities	76,659		583,247
Warrants to purchase redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities			148,650
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities			17,880,180
Stock option awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities	6,252,223	1,337,766	5,366,785
Unvested RSU awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities	453,349
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total weighted-average anti-dilutive securities	100,722

Significant Accounting Polici43

Significant Accounting Policies (Detail Textuals) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)Segment	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)$ / sharesshares
Significant Accounting Policies (Details) [Line Items]
Asset impairment charge		$ 1,416		$ 1,261
Royalty Expense		23,805	$ 20,937	18,673
Advertising Expense		32,198	24,973	$ 22,437
Write-off of Deferred Financing Costs			2,845
Prepayment fees			1,016
Mark-to-market adjustment on certain preferred stock warrants			253
Accounts Receivable, Gross		90,356	68,007
Unbilled Receivables, Current		$ 12,224	$ 7,064
Number of Reportable Segments | Segment		1
Minimum
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		3 years
Definite-lived intangible assets, estimated useful lives		3 years
Maximum
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		5 years
Definite-lived intangible assets, estimated useful lives		10 years
Revenues | Advertising
Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Customer		For the years ended December 31, 2015, no advertising customer accounted for greater than 10% of total revenues.	For the years ended December 31, 2014, no advertising customer accounted for greater than 10% of total revenues.	For the year ended December 31, 2013, one advertising customer accounted for 12% of total revenues.
Concentration Risk, Percentage		10.00%	10.00%	12.00%
Accounts Receivable | Advertising
Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Customer		As of December 31, 2015, no advertising customers accounted for greater than 10% of total accounts receivable.	As of December 31, 2015, no advertising customers accounted for greater than 10% of total accounts receivable.
Concentration Risk, Percentage		10.00%	10.00%
Agency | Accounts Receivable | Advertising
Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Customer		As of December 31, 2015, no advertising agency accounted for greater than 10% of accounts receivable.	As of December 31, 2014, no advertising agency accounted for greater than 10% of accounts receivable.
Concentration Risk, Percentage		10.00%	10.00%
Initial Public Offering
Significant Accounting Policies (Details) [Line Items]
Proceeds from Issuance Initial Public Offering	$ 70,622
Payments for underwriting discounts and commissions and offering costs	$ 8,848
Shares issued, price per share (in dollars per share) | $ / shares	$ 14
Shares Issued Upon Warrants Exercised (in Shares) | shares	149,839
Adjustments to additional paid-in capital warrant liability reclassified	$ 1,140
Common Stock
Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares				330,022
Common Stock | Initial Public Offering
Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares) | shares			5,676,414
Conversion of preferred stock (in Shares) | shares			18,457,235
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in Shares) | shares	339,053
Shares Issued Upon Warrants Exercised (in Shares) | shares	148,650
Internal Software Development Costs
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		3 years
Asset impairment charge		$ 1,416
Website Development Costs
Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		3 years
Asset impairment charge				$ 1,190
Series G Preferred Stock
Significant Accounting Policies (Details) [Line Items]
Shares issued, price per share (in dollars per share) | $ / shares				$ 9
Conversion of preferred stock (in Shares) | shares	2,692,012
Series G Preferred Stock | Initial Public Offering
Significant Accounting Policies (Details) [Line Items]
Conversion of preferred stock (in Shares) | shares	577,055
Redeemable convertible preferred stock | Initial Public Offering
Significant Accounting Policies (Details) [Line Items]
Shares Issued Upon Warrants Exercised (in Shares) | shares	222,977

Acquisitions - Preliminary allo

Acquisitions - Preliminary allocation of the assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Aug. 06, 2015	Mar. 20, 2015	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Goodwill				$ 165,271	$ 127,115
Tea Leaves Health, LLC
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Cash and cash equivalents	$ 296
Accounts receivable	778
Other current assets	19
Property and equipment	3,404
Intangible assets	3,410
Goodwill	23,330
Deferred revenue	(535)
Accounts payable and accrued expenses	(993)
Total consideration paid	$ 29,709
Cambridge BioMarketing Group, LLC
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Accounts receivable		$ 4,406
Other current assets		137
Property and equipment		783
Intangible assets		14,280
Goodwill		15,360
Deferred revenue		(197)
Accounts payable and accrued expenses		(2,659)
Other current liabilities		(53)
Total consideration paid		$ 32,057
DoctorDirectory.com, Inc.
Acquisitions (Details) - Preliminary allocation of the assets acquired and liabilities assumed [Line Items]
Accounts receivable			$ 6,513
Deferred tax asset			81
Other current assets			232
Property and equipment			1,612
Intangible assets			24,970
Goodwill			44,428
Accounts payable and accrued expenses			(1,659)
Deferred tax liability			(10,703)
Total consideration paid			$ 65,474

Acquisitions - Pro forma consol

Acquisitions - Pro forma consolidated net sales and income from continuing operations (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cambridge BioMarketing Group, LLC
Acquisitions (Details) - Pro forma consolidated net sales and income from continuing operations [Line Items]
Revenues	$ 238,858	$ 203,143
Net income (loss)	$ (11,042)	13,119
DoctorDirectory.com, Inc.
Acquisitions (Details) - Pro forma consolidated net sales and income from continuing operations [Line Items]
Revenues		201,335	$ 172,877
Net income (loss)		$ 4,640	$ (12,425)

Acquisitions (Detail Textuals)

Acquisitions (Detail Textuals) - USD ($) $ in Thousands

Aug. 06, 2015

Nov. 30, 2015

May. 31, 2015

Mar. 20, 2015

Nov. 30, 2014

Sep. 30, 2012

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Acquisitions (Details) [Line Items]

Payments to acquire business

$ (47,316)

$ (65,000)

$ (6,736)

Issuance of common stock for acquired business

3,710

919

Due to sellers of acquired business

$ 11,000

11,000

Revenues

81,698

$ 54,314

$ 54,805

$ 41,174

$ 63,049

$ 42,324

$ 41,447

$ 37,505

231,991

184,325

155,850

Pretax income

7,946

$ (5,456)

$ (3,840)

$ (8,986)

$ 11,518

$ 215

$ (246)

$ (7,470)

(10,336)

4,017

(11,895)

Tea Leaves Health, LLC

Acquisitions (Details) [Line Items]

Percentage of voting interests acquired

100.00%

Name of acquired entity

Tea Leaves Health, LLC ("Tea Leaves")

Total purchase price

$ 29,893

Total consideration paid

$ 29,709

Working capital adjustment

184

Shares cancelled

18,251

Tea Leaves Health, LLC | General and administrative expenses

Acquisitions (Details) [Line Items]

Contingent earn out provisions expense incurred

588

Tea Leaves Health, LLC | Sales and marketing expense

Acquisitions (Details) [Line Items]

Contingent earn out provisions expense incurred

1,177

Tea Leaves Health, LLC | Product development expense

Acquisitions (Details) [Line Items]

Contingent earn out provisions expense incurred

4,117

Tea Leaves Health, LLC | Other long-term liabilities

Acquisitions (Details) [Line Items]

Accrued contingent earn-out compensation expense

$ 5,882

5,882

Tea Leaves Health, LLC | Closing

Acquisitions (Details) [Line Items]

Payments to acquire business

$ 15,000

Issuance of common stock in connection with acquisitions (in shares)

327,784

Issuance of common stock for acquired business

$ 3,893

Due to sellers of acquired business

11,000

Tea Leaves Health, LLC | Closing | Former Member

Acquisitions (Details) [Line Items]

Contingent earn-out provisions, eligibility

$ 20,000

Description of earnout will be paid

50% in cash and 50% in shares of the Company's common stock

Cambridge BioMarketing Group, LLC

Acquisitions (Details) [Line Items]

Percentage of voting interests acquired

100.00%

Name of acquired entity

Cambridge BioMarketing Group, LLC ("Cambridge")

Total purchase price

$ 32,273

Total consideration paid

32,057

Working capital adjustment

216

Contingent earn-out provisions, eligibility

5,000

Revenues

20,736

Pretax income

4,651

Cambridge BioMarketing Group, LLC | General and administrative expenses

Acquisitions (Details) [Line Items]

Acquisition-related costs

186

Cambridge BioMarketing Group, LLC | Accounts payable and accrued expenses | Sales and marketing expense

Acquisitions (Details) [Line Items]

Contingent earn out provisions expense incurred

4,913

Cambridge BioMarketing Group, LLC | Closing

Acquisitions (Details) [Line Items]

Payments to acquire business

$ 24,273

Cambridge BioMarketing Group, LLC | Remainder

Acquisitions (Details) [Line Items]

Payments to acquire business

$ 8,000

DoctorDirectory.com, Inc.

Acquisitions (Details) [Line Items]

Name of acquired entity

DoctorDirectory.com, Inc.("DD")

Total consideration paid

$ 65,474

Working capital adjustment

474

Payments to acquire business

$ 65,000

One-time benefit recorded to provision for income taxes

10,033

DoctorDirectory.com, Inc. | General and administrative expenses

Acquisitions (Details) [Line Items]

Acquisition-related costs

$ 21

$ 183

EQAL, Inc.

Acquisitions (Details) [Line Items]

Name of acquired entity

EQAL, Inc. ("EQ")

Contingent earn-out provisions, eligibility

5,000

EQAL, Inc. | Sales and marketing expense

Acquisitions (Details) [Line Items]

Contingent earn out provisions expense incurred

$ 2,211

Discontinued Operations - Loss

Discontinued Operations - Loss from Discontinued Operations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2013USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss from discontinued operations	$ (5,239)
Doctor Solutions business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	7,116
Loss from operations	(3,971)
Loss on sale	(1,268)
Loss from discontinued operations before tax	$ (5,239)
Income tax (provision) benefit
Net loss from discontinued operations	$ (5,239)

Discontinued Operations (Detail

Discontinued Operations (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2013USD ($)
Doctor Solutions business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets	$ 1,000

Prepaid Expenses and Other Cu49

Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid royalties	$ 689	$ 1,225
Prepaid marketing	838	422
Other	3,135	3,882
Total	$ 4,662	$ 5,529

Property and Equipment - Proper

Property and Equipment - Property and equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 104,256	$ 86,236
Less accumulated depreciation and amortization	(75,691)	(60,734)
Total	28,565	25,502
Computer equipment and purchased software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	14,958	12,402
Internally developed software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	43,469	37,226
Acquired technology
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	5,097	1,957
Furniture, fixtures and office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	3,761	2,978
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	7,007	6,381
Website development costs
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 29,964	$ 25,292

Property and Equipment - Deprec

Property and Equipment - Depreciation and amortization expense (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Depreciation and amortization expense [Abstract]
Sales and marketing	$ 1,190	$ 1,286	$ 1,183
Product development	12,764	10,811	10,325
General and administrative	324	327	350
Total depreciation and amortization	$ 14,278	$ 12,424	$ 11,858

Property and Equipment (Detail

Property and Equipment (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Internally developed software costs capitalized	$ 7,774	$ 8,870	$ 7,416
Unamortized internally developed software	12,228	13,078
Amortization expense of internally developed software	$ 7,092	$ 6,583	$ 5,198

Goodwill and Other Intangible53

Goodwill and Other Intangible Assets - Schedule of definite-lived intangible assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 68,975	$ 49,815
Accumulated amortization		(25,229)	(19,099)
Total		43,746	30,716
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		40,090	27,300
Accumulated amortization		(14,206)	(11,247)
Total		$ 25,884	$ 16,053
Weighted- average remaining useful life	[1]	8 years 10 months 24 days	9 years 6 months
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 24,985	$ 18,615
Accumulated amortization		(7,123)	(4,370)
Total		$ 17,862	$ 14,245
Weighted- average remaining useful life	[1]	6 years 4 months 24 days	6 years 6 months
Other intangibles
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 3,900	$ 3,900
Accumulated amortization		$ (3,900)	(3,482)
Total			$ 418
Weighted- average remaining useful life	[1]		8 months 12 days
[1]	The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period.

Goodwill and Other Intangible54

Goodwill and Other Intangible Assets - Schedule of future amortization expense of intangible assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,016	$ 6,071
2,017	6,063
2,018	5,755
2,019	5,574
2,020	5,552
Thereafter	14,731
Total	$ 43,746	$ 30,716

Goodwill and Other Intangible55

Goodwill and Other Intangible Assets (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Other Intangible Assets (Details) [Line Items]
Goodwill	$ 165,271	$ 127,115
Amortization of Intangible Assets	6,130	2,519	$ 3,592
DD
Goodwill and Other Intangible Assets (Details) [Line Items]
Goodwill		44,962
Definite-lived intangible assets		23,500
One-time benefit recorded to provision for income taxes	601	$ 10,033
Goodwill, Period Increase (Decrease)	(534)
Finite-Lived Intangible Assets, Period Increase (Decrease), Total	1,470
Cambridge And Tea Leaves Acquisitions
Goodwill and Other Intangible Assets (Details) [Line Items]
Goodwill	38,690
Definite-lived intangible assets	17,690
Customer relationships | Cambridge Biomarketing Group Llc
Goodwill and Other Intangible Assets (Details) [Line Items]
Definite-lived intangible assets	$ 8,810
Finite-Lived Intangible Asset, Useful Life	10 years
Customer relationships | Tea Leaves Health Llc
Goodwill and Other Intangible Assets (Details) [Line Items]
Definite-lived intangible assets	$ 2,510
Finite-Lived Intangible Asset, Useful Life	10 years
Trade names | Cambridge Biomarketing Group Llc
Goodwill and Other Intangible Assets (Details) [Line Items]
Definite-lived intangible assets	$ 5,470
Finite-Lived Intangible Asset, Useful Life	10 years
Trade names | Tea Leaves Health Llc
Goodwill and Other Intangible Assets (Details) [Line Items]
Definite-lived intangible assets	$ 900
Finite-Lived Intangible Asset, Useful Life	3 years

Accounts Payable and Accrued 56

Accounts Payable and Accrued Expenses - Accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued expenses [Abstract]
Accounts payable	$ 12,638	$ 8,563
Accrued compensation	4,676	8,260
Accrued acquisition earn-outs	6,338	1,425
Accrued royalties	6,184	5,991
Accrued media and licensed content	3,583	3,716
Accrued interest	1,275	408
Accrued professional fees	623	718
Other accrued expenses	3,246	2,641
Total	$ 38,563	$ 31,722

Long-Term Debt - (Details)

Long-Term Debt - (Details) $ in Thousands	Dec. 31, 2015USD ($)
Debt Disclosure [Abstract]
2,016	$ 6,775
2,017	6,775
2,018	6,775
2,019	90,731
Total	$ 111,056

Long-Term Debt (Detail Textuals

Long-Term Debt (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015	Mar. 01, 2015	Nov. 30, 2014	Nov. 01, 2014	Mar. 31, 2014
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate Description		The interest rate on the Credit Facility is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on the Company's consolidated leverage ratio, as defined in the Credit Facility agreement, and there is a 0.50% commitment fee on the unused portion of the Revolver.
Write-off of Deferred Financing Costs			$ 2,845
Debt Prepayment Fees			1,016
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$ 0.015
Payments of Financing Costs		$ 792	2,899	$ 68
Amortization of Financing Costs		540	528	1,646
Former Revolver
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 30,000
Line of Credit Facility, Maximum Borrowing Capacity of Eligible Accounts Receivable				80.00%
Former Term Loan
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 8,500
Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 82,250				$ 35,000
Remaining revolver borrowing capacity		37,250
Credit Facility Outstanding Balance		$ 45,000	30,000
Commitment fee percentage on unused portion		0.50%
Revolving Credit Facility | DD
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							$ 55,000
Term Loan Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity									$ 40,000
Credit Facility Outstanding Balance		$ 66,056	$ 60,000		$ 67,750	$ 59,250
Term Loan Facility | DD
Debt Instrument [Line Items]
Credit Facility Outstanding Balance							$ 60,000	$ 39,000
Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate at Period End		4.33%	3.48%
Credit Facility | Minimum | LIBOR
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate at Period End		2.75%
Credit Facility | Maximum | LIBOR
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate at Period End		4.00%
IPO
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)	149,839
Adjustments to additional paid-in capital warrant liability reclassified	$ 1,140
Common Stock | Former credit facility
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)			592,501
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.015
Common Stock | IPO
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)			148,650
Series F redeemable convertible preferred stock | Former credit facility
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)			112,959
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 7.61
Series C redeemable convertible preferred stock | Former credit facility
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)			110,018
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 3.27
Preferred Stock | IPO
Debt Instrument [Line Items]
Shares Issued Upon Warrants Exercised (in Shares)	222,977

Common Stock and Preferred St59

Common Stock and Preferred Stock (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Common Stock and Preferred Stock
Preferred Stock, Shares Issued			0	0
Preferred Stock, Shares Outstanding			0	0
Stockholders' Equity, Reverse Stock Split		In March 2014, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation effecting a 1-for-1.5 reverse stock split of the Company’s issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements and related notes thereto have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on March 14, 2014.
Common Stock, Shares Authorized	90,000,000		90,000,000	90,000,000
Preferred Stock, Shares Authorized	10,000,000		10,000,000	10,000,000
Conversion Price IPO Adjustment Threshold (in Dollars per share)			$ 11.88
Preferred Stock, Redemption Price Per Share (in Dollars per share)	$ 14
Class of Warrant or Right, Outstanding		100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.015
Deferred Costs and Other Assets (in Dollars)				$ 1,131
Initial Public Offering
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)	$ 14
Ratchet provision
Common Stock and Preferred Stock
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock	577,055
Series A
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					$ 0.50
Series B
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					1.77
Series C
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					3.27
Series D
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					6.87
Series E
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					7.98
Series F
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					7.61
Series G
Common Stock and Preferred Stock
Shares Issued, Price Per Share (in Dollars per share)					$ 9
Redeemable convertible preferred stock, Shares Issued and Oustanding	3,172,436
Stock Issued During Period, Shares, Conversion of Convertible Securities	2,692,012
Series G | Initial Public Offering
Common Stock and Preferred Stock
Stock Issued During Period, Shares, Conversion of Convertible Securities	577,055
Series G | Effect of 1-for-1.5 stock split
Common Stock and Preferred Stock
Conversion Price IPO Adjustment Increased Price (in Dollars per share)	$ 17.82
Series G | Ratchet Provision Deemed Dividend
Common Stock and Preferred Stock
Dividends, Stock (in Dollars)	$ 8,079
Series A, Series B, Series C, Series D, Series E and Series F redeemable convertible preferred stock
Common Stock and Preferred Stock
Redeemable convertible preferred stock, Shares Issued and Oustanding	23,647,834
Stock Issued During Period, Shares, Conversion of Convertible Securities	15,765,223
2014 Equity Incentive Plan
Common Stock and Preferred Stock
Common Stock, Capital Shares Reserved for Future Issuance			422,478
2014 Employee Stock Purchase Plan
Common Stock and Preferred Stock
Common Stock, Capital Shares Reserved for Future Issuance			405,084

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of stock option activity (Details) - Stock option activity - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Number of options
Outstanding	5,893,698	5,457,791		5,271,707
Granted, Number of options	939,165	1,945,851	[1]	901,476
Exercised	(358,077)	(1,139,891)		(183,501)
Cancelled	(482,841)	(370,053)		(531,891)
Outstanding	5,991,945	5,893,698		5,457,791	5,271,707
Exercisable at December 31, 2015	4,215,575
Weighted-average exercise price
Outstanding	$ 9.94	$ 7.61		$ 7.28
Granted, Weighted-average exercise price	12.03	14.67	[1]	9.41
Exercised, Weighted-average exercise price	7.23	6.41		4.31
Cancelled, Weighted-average exercise price	12.81	10.52		7.67
Outstanding	10.21	$ 9.94		$ 7.61	$ 7.28
Exercisable at December 31, 2015	$ 9.05
Outstanding, Weighted-average remaining contractual life	5 years 3 months 18 days	6 years 5 months 23 days		6 years 6 months 15 days	7 years 4 days
Exercisable at December 31, 2015	4 years 1 month 28 days
Outstanding, Aggregate intrinsic value	$ 442	$ 29,249		$ 20,396	$ 10,556
Exercisable at December 31, 2015	$ 442
[1]	The Company granted 112,500 performance-based options in 2014 where such options vested and became exercisable over approximately nine months from the date of grant, dependent upon the Company meeting certain performance criteria. The performance criteria for these options were met at less than target, which resulted in the vesting of 90,555 of such 112,500 shares on December 31, 2014. The remaining 21,945 shares were cancelled on December 31, 2014.

Stock-Based Compensation - Sc61

Stock-Based Compensation - Schedule of weighted-average assumptions (Details) - Stock Options	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	43.36%	49.28%	50.32%
Expected life (years)	6 years 3 months	6 years 3 months	6 years 3 months
Risk-free interest rate	1.73%	1.92%	1.54%
Dividend yield

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Unit Awards (Details) - Restricted Stock	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Number of RSUs
Outstanding at December 31, 2014 | shares
Granted | shares	882,001	[1]
Vested | shares	(279,986)
Cancelled | shares	(53,175)
Outstanding at December 31, 2015 | shares	548,840
Weighted Average Grant Date Fair Value
Outstanding at December 31, 2014 | $ / shares
Granted | $ / shares	$ 10.80	[1]
Vested | $ / shares	8.27
Cancelled | $ / shares	11.99
Outstanding at December 31, 2015 | $ / shares	$ 11.97
[1]	RSUs granted during the year ended December 31, 2015 include the grant of 40,000 units of performance-based RSUs that are dependent upon the Company meeting certain performance criteria. The Company has adjusted stock-based compensation expense recognized to-date to reflect estimated performance related to these awards.

Stock-Based Compensation (Detai

Stock-Based Compensation (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 1,675	$ 8,080	$ 1,146
Proceeds from Stock Options Exercised	$ 2,633	$ 7,939	$ 101
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$ 5.33	$ 7.53	$ 4.80
Allocated Share-based Compensation Expense	$ 5,751	$ 7,920	$ 3,039
Unrecognized compensation expense related to unvested stock options	$ 3,804
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 2 months 9 days
Total fair value of stock options vested	$ 6,123	4,328	3,668
Performance based RSUs granted during period	40,000
Total grant date fair value of RSUs vested during the year	$ 1,739
Stock based compensation expense related to RSUs	$ 4,845
2014 Plan
Stock-Based Compensation (Details) [Line Items]
Common stock, aggregate shares issued, description	The aggregate number of shares of the Company's common stock that may be issued pursuant to the 2014 Plan is the sum of (1) 200,000 shares, (2) the 388,781 shares reserved for issuance under the 2003 Plan at the time the 2014 Plan became effective, and (3) any shares subject to outstanding stock options that would otherwise have returned to the 2003 Plan (such as upon the expiration or termination of stock options prior to vesting).
Common stock, number of shares reserved for issuance, description	In addition, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year from January 1, 2015 through January 1, 2024 by the lesser of (a) 4% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year and (b) a number of shares determined by the Board of Directors.
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	422,478
Employee Stock
Stock-Based Compensation (Details) [Line Items]
Common stock, number of shares reserved for issuance, description	The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year from January 1, 2015 through January 1, 2024 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 400,000 shares and (c) a number determined by the Board of Directors that is less than (a) and (b).
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	405,084
Allocated Share-based Compensation Expense	$ 340	$ 1,180
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				500,000
Common stock, purchase for participating employee price, description	Unless otherwise determined by the Board of Directors, common stock will be purchased for participating employees at a price per share equal to the lower of (a) 85% of the fair market value of a share of the common stock on the first date of an offering, or (b) 85% of the fair market value of a share of the common stock on the date of purchase.
Employee stock purchase plan weighted average price	$ 7.40	$ 11.52
Contribution Percentage	15.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	271,623	138,184
Performance-based options
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)		112,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)		90,555
Stock Issued During Period, Shares, Share-based Compensation, Forfeited (in Shares)		21,945
RSUs
Stock-Based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 1 month 28 days
Unrecognized compensation expense related to unvested RSUs	$ 3,244
Discontinued Operations
Stock-Based Compensation (Details) [Line Items]
Allocated Share-based Compensation Expense	$ 0	$ 0	$ 70

Income Taxes - Provision (benef

Income Taxes - Provision (benefit) from continuing operations for income taxes (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Provision (benefit) from continuing operations for income taxes [Abstract]
Federal									$ (84)	$ (250)
State									(225)	(110)	$ (95)
Foreign									(43)	(45)	(45)
Total current									(352)	(405)	(140)
Federal									(741)	7,058	(749)
State									(211)	2,013	(213)
Total deferred									(952)	9,071	(962)
Total (provision) benefit	$ (494)	$ (7,262)	$ 5,534	$ 918	$ 9,669	$ (365)	$ (349)	$ (289)	$ (1,304)	$ 8,666	$ (1,102)

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 39,478	$ 40,899
Allowance for doubtful accounts	372	258
Intangible and other assets	1,912	1,595
Deferred revenue	158	190
Stock-based compensation	11,129	9,504
Accrued expenses and other	5,893	4,038
AMT credit	334	250
Depreciation	372	1,722
Total deferred tax assets	59,648	58,456
Valuation allowance	(51,185)	(46,577)
Net deferred tax assets	$ 8,463	11,879
Deferred tax liabilities:
Depreciation		(69)
Goodwill	$ (5,452)	(6,028)
Intangible and other assets	(10,581)	(11,799)
Total deferred tax liabilities	(16,033)	(17,896)
Net deferred tax liabilities	$ (7,570)	$ (6,017)

Income Taxes - Reconcilation Be

Income Taxes - Reconcilation Between Statutory and Effective Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconcilation Between Statutory and Effective Tax Rate [Abstract]
(Provision) benefit at statutory rate									$ 3,618	$ (1,406)	$ 4,163
Permanent items									(467)	(885)	(311)
State taxes									(283)	1,228	(210)
Changes in valuation allowance									(4,172)	9,729	(4,744)
Total (provision) benefit	$ (494)	$ (7,262)	$ 5,534	$ 918	$ 9,669	$ (365)	$ (349)	$ (289)	$ (1,304)	$ 8,666	$ (1,102)

Income Taxes (Detail Textuals)

Income Taxes (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes (Details) [Line Items]
Deferred Tax Liabilities Increase (Decrease)	$ 1,553
Operating loss carryforwards	104,042
DD
Income Taxes (Details) [Line Items]
One-time benefit recorded to provision for income taxes	601	$ 10,033
Deferred Compensation, Share-based Payments
Income Taxes (Details) [Line Items]
Operating loss carryforwards	$ 7,517

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases (Details) $ in Thousands	Dec. 31, 2015USD ($)
Operating Leases [Abstract]
2,016	$ 5,078
2,017	4,685
2,018	3,638
2,019	3,529
2,020	3,689
Thereafter	11,366
Sublease rentals	(1,146)
Net lease commitments	$ 30,839

Commitments and Contingencies69

Commitments and Contingencies - Minimum Guaranteed Payments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Minimum Guaranteed Payments [Abstract]
2,016	$ 14,926
2,017	12,257
2,018	12,135
2,019	12,322
2,020	12,889
Thereafter	10,000
Total	$ 74,529

Commitments and Contingencies70

Commitments and Contingencies (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Rent Expense, Net	$ 4,496	$ 3,625	$ 3,377
Operating Leases, Rent Expense, Sublease Rentals	$ 922	$ 427	$ 102

Benefit Plan (Detail Textuals)

Benefit Plan (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 821	$ 487	$ 409

Related-Party Transactions (Det

Related-Party Transactions (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Consulting services
Related-Party Transactions (Details) [Line Items]
Costs and Expenses, Related Party	$ 142

Supplemental Disclosure of Ca73

Supplemental Disclosure of Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Supplemental disclosure of cash flow information:
Interest paid	$ 3,850	$ 3,734	$ 6,173
Income taxes paid	126	341	73
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock for acquired business	3,677	919	2,921
Warrants issued in connection with credit facilities			149
Warrants issued in connection with website partner agreement		1,131
Capital lease obligations incurred	90	466	879
Due to sellers of acquired business	$ 11,000
Amounts due from stock option exercises		$ 43	$ 688

Subsequent Events (Detail Textu

Subsequent Events (Detail Textuals) - USD ($) $ in Thousands	Mar. 02, 2016	Feb. 29, 2016	Dec. 31, 2015	Mar. 31, 2015	Mar. 01, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Due to sellers of acquired business			$ 11,000
Revolving Credit Facility
Subsequent Event [Line Items]
Credit Facility Outstanding Balance			45,000			$ 30,000
Term Loan Facility
Subsequent Event [Line Items]
Credit Facility Outstanding Balance			$ 66,056	$ 67,750	$ 59,250	$ 60,000
Subsequent event | Tea leaves purchase agreement amendment
Subsequent Event [Line Items]
Due to sellers of acquired business		$ 11,000
Paid to Seller of acquired business		5,000
Purchase consideration payable		3,000
Interest due to seller		200
Advance Earn Out Payment Eligibility		5,000
Contingent earn-out provisions, eligibility		20,000
Remaining earn out payment eligibility		$ 15,000
Description Of Earnout		50% in cash and 50% in shares of the Company's common stock
Subsequent event | Tea leaves purchase agreement amendment | Full Payment Election
Subsequent Event [Line Items]
Remaining Interest due to seller		$ 50
Subsequent event | Tea leaves purchase agreement amendment | Partial Payment Election
Subsequent Event [Line Items]
Remaining Interest due to seller		$ 400
Subsequent event | Credit facility amendment | Revolving Credit Facility
Subsequent Event [Line Items]
Amount drew under revolver credit facility	$ 15,000
Credit Facility Outstanding Balance	60,000
Amount available to be drawn	22,250
Subsequent event | Credit facility amendment | Term Loan Facility
Subsequent Event [Line Items]
Credit Facility Outstanding Balance	$ 64,363

Quarterly Financial Data (Una75

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues
Advertising and sponsorship revenues	$ 72,900	$ 49,630	$ 50,225	$ 36,338	$ 58,981	$ 37,910	$ 36,882	$ 32,692	$ 209,093	$ 166,465	$ 134,893
Premium services revenues	8,798	4,684	4,580	4,836	4,068	4,414	4,565	4,813	22,898	17,860	20,957
Total revenues	81,698	54,314	54,805	41,174	63,049	42,324	41,447	37,505	231,991	184,325	155,850
Operating expenses:
Cost of revenues	23,284	15,637	13,926	14,076	15,908	11,006	10,961	11,421	66,923	49,296	43,338
Sales and marketing	22,464	18,531	21,041	12,725	13,956	12,213	12,216	10,220	74,761	48,605	44,385
Product development	16,968	14,163	12,187	12,602	12,088	10,886	10,805	10,762	55,920	44,541	43,759
General and administrative	9,608	10,010	10,065	9,804	8,816	7,504	7,126	6,595	39,487	30,041	27,462
Total operating expenses	72,324	58,341	57,219	49,207	50,768	41,609	41,108	38,998	237,091	172,483	158,944
Income (loss) from operations	9,374	(4,027)	(2,414)	(8,033)	12,281	715	339	(1,493)	(5,100)	11,842	(3,094)
Interest expense, net	(1,428)	(1,429)	(1,426)	(953)	(763)	(500)	(585)	(1,863)	(5,236)	(3,711)	(8,442)
Other expense								(4,114)		(4,114)	(359)
Income (loss) from continuing operations before (provision) benefit for income taxes	7,946	(5,456)	(3,840)	(8,986)	11,518	215	(246)	(7,470)	(10,336)	4,017	(11,895)
(Provision) benefit for income taxes	(494)	(7,262)	5,534	918	9,669	(365)	(349)	(289)	(1,304)	8,666	(1,102)
Net income (loss)	$ 7,452	$ (12,718)	$ 1,694	$ (8,068)	21,187	(150)	(595)	(7,759)	$ (11,640)	12,683	$ (18,236)
Series G preferred stock deemed dividend							(8,079)			$ (8,079)
Net income (loss) attributable to common stockholders					$ 21,187	$ (150)	$ (8,674)	$ (7,759)
Net income (loss) attributable to common stockholders per common share:
Basic (in Dollars per share)	$ 0.23	$ (0.40)	$ 0.05	$ (0.26)	$ 0.68	$ 0	$ (0.29)	$ (1.44)	$ (0.36)	$ 0.19	$ (3.57)
Diluted (in Dollars per share)	$ 0.23	$ (0.40)	$ 0.05	$ (0.26)	$ 0.64	$ 0	$ (0.29)	$ (1.44)	$ (0.36)	$ 0.17	$ (3.57)
Weighted-average common shares outstanding:
Basic (in Shares)	32,482,159	32,138,214	31,755,107	31,525,559	31,076,588	30,404,529	29,802,970	5,403,846	31,977,246	24,259,395	5,103,351
Diluted (in Shares)	32,904,143	32,138,214	33,373,407	31,525,559	32,977,544	30,404,529	29,802,970	5,403,846	31,977,246	26,911,782	5,103,351